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In Vivo Characterization of G Protein-Coupled Estrogen Receptor in
Mammary Tumorigenesis
Nicole A. Marjon, MS, PhD, Biomedical Sciences, University of New
Mexico, 2015
ABSTRACT
The steroid hormone, estrogen (17β-estradiol or E2), is involved in numerous and
varied physiological processes. Until recently, all E2-dependent effects were thought to
be propagated exclusively through the classical estrogen receptors (ERs), ERα and ERβ.
However, in double ERα/β knockout mice, select E2-dependent effects remain,
suggesting the existence of additional E2 receptors, such as the G protein-coupled
estrogen receptor (GPER) 1.
E2 plays a central role in the progression of breast cancer, and inhibiting E2
signaling in women with breast cancer increases long-term survival. The role of GPER in
breast cancer is largely unknown. E2 stimulation of GPER activates the mitogen
activated protein kinase (MAPK) cascade as well as phosphoinositide 3-kinase (PI3K),
suggesting a role for GPER in proliferation and cell survival. Additionally, GPER is
responsible for E2-dependent proliferation in select breast cancer cells in vitro.
Clinically, GPER expression is correlated with increased size of the primary tumor and
occurrence of distant metastasis. Although these data implicate GPER in breast
carcinogenesis, its role in vivo, where tumor cells exist in a complex microenvironment,
remains unclear. Therefore, this study focuses on the in vivo effects of GPER on
mammary tumorigenesis.
GPER KO mice were bred with MMTV-PyMT mice, a model of mammary
carcinogenesis, to determine the effects of GPER expression on tumor development and
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progression. Tumor latency and extent of hyperplasia was unaffected, suggesting GPER
does not play a role in early tumor development. However, in late stage tumorigenesis,
GPER KO mice displayed smaller tumors and decreased metastases, demonstrating a role
for GPER in tumor growth and progression. To distinguish the effects of GPER in the
tumor parenchyma and microenvironment, GPER expressing PyMT tumor epithelial cells
(WT/PyMT) or GPER KO PyMT cells (KO/PyMT) were each orthotopically transplanted
into GPER WT and GPER KO recipient mice, and analyzed for tumor growth and
metastasis. WT/PyMT tumor size was unaffected by the microenvironment, whereas
KO/PyMT tumors were larger in KO recipient mice compared to WT recipient mice.
With respect to metastasis, WT/PyMT mice metastasized more frequently in WT
compared with KO mice, while KO/PyMT cell metastasis was unaffected by the
microenvironment. These data suggest GPER expression in the tumor microenvironment
and epithelium differentially regulates tumor growth and metastasis. Finally, because
GPER expression regulates tumor progression, the effects of administering a GPERselective agonist or antagonist in the PyMT model were determined. While the GPERselective agonist G-1 did not affect tumor size or metastasis, the GPER-selective
antagonist G36 decreased E2-mediated metastasis.
Together, these data are the first in vivo demonstration of GPER augmenting
tumor growth and progression. Further, pharmacologically inhibiting GPER decreases
metastasis, suggesting GPER could be a viable candidate for targeted therapy in breast
cancer.
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CHAPTER 1
INTRODUCTION

1

1.1 ESTROGEN
Estrogen is the primary female sex hormone and is in the family of steroid
hormones,

which

includes

glucocorticoids,

mineralocorticoids,

androgens,

and

progestins. There are three naturally occurring estrogens produced by humans including
estrone (E1), estradiol (E2), and estriol (E3), and are named based on the number of
hydroxyl groups they contain. E1 has one hydroxyl group, E2 has two hydroxyl groups,
and E3 contains three hydroxyl groups (Figure 1.1). E1 is the predominant estrogen
produced in post-menopausal women and is produced primarily by adipocytes (1), while
E3 is produced by the placenta and is the predominant circulating estrogen during
pregnancy (3). E2 is the principal circulating estrogen in premenopausal women and is
well characterized in the regulation of the female reproductive system (4). There are two
E2 isoforms, 17α-E2 and 17β-E2; however, 17β-E2 is the more physiologically active E2
and will be abbreviated as E2 throughout this dissertation (5).

2

Figure 1.1 Physiologic estrogens. Chemical structures of the three naturally
occurring estrogens.

3

1.1.1 Estrogen Synthesis and Regulation
In females, the primary site of E2 synthesis is the ovarian follicle, although the
liver, adrenal gland, adipocytes, bone, vascular endothelium, and regions of the brain also
produce comparatively low amounts of E2 (4, 6, 7). These extra-ovarian sites of estrogen
production, especially adipocytes, are important for the generation of E2 in postmenopausal women. In the ovarian follicle, there is cooperation between thecal and
granulosa cells to convert cholesterol to E2 (8, 9). Through a multistep process in the
thecal cell, cholesterol is converted to androstenedione or testosterone (8). Because the
thecal cell does not express aromatase, the p450 enzyme required to convert androgens to
estrogens, androstenedione and testosterone are transported to the granulosa cell, where
androstenedione and testosterone are aromatized producing E1 and E2, respectively (10,
11). The majority of E1 is subsequently converted to E2 in the granulosa cell or
peripheral tissues (Figure 1.2A).
The biosynthesis of E2 in the ovary is tightly regulated by the hypothalamus and
pituitary gland. The hypothalamus releases gonadotropin releasing hormone (GnRH),
which signals to the pituitary gland to release luteinizing hormone (LH) and follicle
stimulating hormone (FSH). LH receptors (LHRs) are present at a high concentration on
thecal cells, and stimulation of LHR induces the conversion of cholesterol to
androsteindione (9). Simultaneously, FSH binds to FSH receptors (FSHRs) found on
granulosa cells and activates aromatase, converting androsteindione to E1 or testosterone
to E2 (12). E2 at high levels feeds back to the hypothalamus to inhibit the production of
GnRH (Figure 1.2B) (8, 9). This negative feedback loop results in cyclic production of
E2 in females of reproductive age and controls the menstrual cycle. The ovarian
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production of E2 ceases when women enter menopause, which typically occurs in the
fourth or fifth decade of life.

5

Figure 1.2 Ovarian E2 production. A. Premenopausal production of estradiol occurs in
the ovarian follicle thecal and granulosa cells. In the thecal cell, LH stimulates the
conversion of cholesterol to androsteindione, which is transported to the granulosa cell
and converted to estrone or testosterone and ultimately estradiol. Aromatase (ARO) is
responsible for the conversion of androgens to estrogens and is positively regulated by
FSH. B. The hypothalamus secretes gonadotropin releasing hormone (GnRH), which
stimulates the pituitary gland to secrete LH and FSH, which act on the ovarian follicle to
stimulate E2 production. Secreted E2 subsequently inhibits hypothalamic GnRH release.
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1.2 Classical Estrogen Receptors
In 1930, E2 was identified as the ovarian-derived hormone when it was purified in
crystalized form in the laboratory of Allen and Doisy (13). Early reports described a role
for E2 in sexual maturity due to E2-dependent actions, including increased uterine wet
weight, modified vaginal tissue, and vaginal and uterine proliferation (13). It was
believed that E2 regulated metabolism in the absence of a specific E2 receptor until the
development of tritiated E2 ([3H]E2) (14). In the Jensen laboratory, [3H]E2 was
administered to female rats and was exclusively retained by estrogen responsive tissues,
including the uterus and vagina where it caused proliferation. The retention of E2 and E2dependent proliferation were blocked by the antiestrogen nafoxidine in a dose dependent
manner, providing evidence for the existence of an E2 receptor (14). In 1973, the first
estrogen receptor (ER) was extracted from rat uterus and was renamed ERα subsequent
to the discovery of the second ER, ERβ, in 1996 (15, 16). ERα and ERβ are designated
classical ERs. Classical ERs have a similar basic structure consisting of five domains
designated A/B, C, D, E, and F (Figure 1.3A), with >60% overall sequence homology
(17‐19). Like other steroid receptors, ERα/β act as transcription factors after binding
their ligand. The E domain is required for estrogen binding and the C domain is
responsible for DNA binding (20). The E domain also contains activation function 2
(AF2) that is involved in ligand-dependent activation of transcription. In the amino
terminal A/B domain, ERα also contains activation function 1 (AF1) responsible for
ligand-independent activity (19).
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1.2.1 Classical ER Signaling
ERα and ERβ are located primarily in the nucleus and stabilized in their inactive
form by association with heat shock proteins (HSPs) (14). When activated by E2
binding, the classical ERs are released from HSPs, dimerize, and bind to estrogen
response elements (EREs) in DNA where they recruit coactivators and corepressors to
modulate target gene expression (21). Typically ERα binds to EREs to regulate
transcription; however, using an ERα mutant that is unable to interact with DNA,
Jakacka et al demonstrated ERα is also capable of interacting with transcription factors,
coregulators, and corepressors to modulate gene expression independent of direct DNA
binding (22). In another non-classical pathway, ligand-independent activation of the
classical ERs occurs through MAPK-dependent phosphorylation of ERα, regulating
transcription of ERα target genes (23, 24). These three pathways of ERα/β activity
culminate in the modulation of transcription and are therefore classified as long-term
genomic responses. This is in contrast to activation of rapid, non-genomic signaling
typically occurring downstream of membrane-associated receptors (Figure 1.3B).
Rapid, non-genomic signaling is defined by the activation of second messengers
such as andenylyl cyclase or phospholipase C (PLC), and generally occurs on the order of
seconds to minutes. Although ERα acts predominantly as a transcription factor, it has
been reported to associate with the membrane through palmitoylation of its E domain and
in that location to activate second messengers. Membrane-associated ERα (mERα)
associates with caveolin 1. When bound by E2, mERα dimerizes and associates with
heterotrimeric guanine nucleotide-binding (G) proteins to produce cAMP, initiate Ca++
mobilization, and stimulate kinase cascades (25). One of the best-described roles for
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mERα is the production of NO in the vasculature leading to vasodilation, which has been
verified in vivo (26). Another widely investigated role for mERα is cellular proliferation
in the absence of nuclear ERα-mediated transcription. In breast cancer cell lines, mERα
transactivates epidermal growth factor receptor (EGFR) and insulin-like growth factor 1
receptor, thereby phosphorylating ERK and increasing cell proliferation (25). While this
is an intriguing role for mERα, the prevalence of mERα in human breast cancer samples
is debated (Figure 1.3B) (27).
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Figure 1.3 Classical ER structure and signaling. A. ERα has five major domains. DNA
binding occurs in the C domain and the E domain is responsible for ligand binding. These
domains are separated by the “hinge” region D domain. The N terminal activation
function 1 (AF1) domain is required for ligand‐independent transcription, while the
activation function 2 (AF2) domain located in the C terminus and is responsible for
ligand‐dependent transcription. ERβ has a similar structure to ERα. B. Classically, E2
binds ERα/β in the nucleus releasing the receptor from heat shock proteins (HSP). The
receptors dimerize and bind to estrogen response elements (EREs) in the DNA to
modulate transcription. Additionally, once activated ERα/β can bind transcription factors
to regulate transcription of genes not traditionally defined as estrogen‐responsive genes.
Ligand‐independent ERα activation also occurs through kinase signaling downstream of
growth factor receptors through phosphorylation of ERα. Lastly, ERα associates with the
cell membrane (mER) and activates rapid, non‐genomic signaling. In cultured breast
cancer cells, mER transactivates growth factor receptors, enhancing proliferation.
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1.3 G protein-Coupled Estrogen Receptor 1
A double ERα/β knockout mouse was generated to enhance the understanding of
E2 and its receptors in normal physiology. The majority of E2-dependent effects were
abolished in the double knockout mice; however, some rapid E2-dependent actions
remained. Further, in cell lines, rapid E2 signaling remained in the presence of the ERα
antagonist ICI-182,780, or were induced by this compound (28). These observations
suggested the existence of a novel E2 receptor later determined to be the G proteincoupled receptor (GPCR) GPR30, which has been renamed G protein-coupled estrogen
receptor 1 (GPER).

1.3.1 GPCR Biology
GPCRs are defined by their structure and interaction with G proteins. While many
receptor types can interact with heterotrimeric G proteins, including receptor tyrosine
kinases and classical steroid receptors, the term GPCR typically refers to a family of
seven-transmembrane domain receptors.

GPCRs are classically present on the cell

membrane. When activated by their ligands, GPCRs recruit G proteins and initiate rapid
downstream signaling via activation of adenylyl cyclase and PLC (29). Following
activation, GPCRs are rapidly phosphorylated by a G protein-coupled receptor kinase
(GRK), which recruits arrestins to bind the C-terminal tail of GPCRs, which in turn
sterically block interactions with G proteins, inhibiting further signaling. Arrestins then
initiate their own signaling cascade to facilitate trafficking of GPCRs targeted for
recycling or degradation (30, 31). Arrestins have also been implicated in GPCRdependent transactivation of tyrosine kinase receptors (32).
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GPCRs are involved in a wide variety of physiologic activities, and 40% of
currently prescribed pharmaceutical drugs target this receptor superfamily. It has been
predicted through whole genome-sequence analysis that more than 800 GPCRs exist in
the human genome. Roughly 300 GPCRs are believed to be olfactory receptors, and of
the remaining receptors, over 100 have no known ligand and are classified as orphan
receptors (33).

1.3.2 Discovery and Characterization of GPER
In the 1990’s, many research groups cloned orphan GPCRs with the goal of
identifying their natural ligands and physiologic functions. In the late 1990’s, GPR30 was
cloned and reported to be expressed at higher levels in ERα+ (MCF7) breast cancer cells
as compared to ERα- (MDA-MB-231) breast cancer cells, leading Filardo and colleagues
to hypothesize GPR30 was involved in rapid E2 signaling (34, 35). To test this
hypothesis, ERK1/2 signaling was evaluated in MCF7 (ERα/β+, GPR30+), SKBR3
(ERα/β-, GPR30+), and MDA-MB-231 (ERα-, ERβ+, GPR30-) cell lines. E2-dependent
ERK1/2 phosphorylation (P-ERK1/2) was stimulated in MCF7 and SKBR3 cells, but it
was absent in MDA-MB-231 cells. Further, P-ERK1/2 could be induced in MDA-MB231 cells transfected with a GPR30 plasmid in response to E2, tamoxifen, and ICI182,780, but not in response to 17α-estradiol or progesterone (35). These data suggested
GPR30 expression was required to activate rapid E2-dependent signaling; however, there
was no evidence that E2 interacted with the receptor.
In 2005, two groups independently demonstrated E2 binding to GPR30expressing cells. In one report, Thomas et al. demonstrated that [3H]E2 bound to
membranes of SKBR3 cells that are GPR30+ and ERα/β- with high affinity (Kd = 3.3
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nM), while testosterone, progesterone, and cortisol were unable to bind. Unlike the
classical ERs, E1 and E3 displayed an extremely low binding affinity with a relative
binding affinity (RBA) of <1% when compared to E2. As previously proposed,
tamoxifen and ICI-182,780 were able to bind to GPR30 with a 10% RBA as compared to
E2. To confirm these results, [3H]E2 binding was examined in the presence and absence
of GPR30 transfection in HEK293 cells, which do not express the classic E2 receptors or
GPR30. E2 binding was observed in GPR30-transfected HEK293 cells, but not in
untransfected cells (36). In the second report, Ravenkar et al. used fluorescently labeled
E2 to examine the binding affinity as well as location of estrogen binding in GPR30transfected COS7 cells, which lack both classical ERs and GPR30. In addition, a fusion
protein of GPR30 and green fluorescent protein (GFP) was exogenously expressed in
COS7 to determine cellular location. GPR30 was located intracellularly on the
endoplasmic reticulum and Golgi apparatus, in contrast to the classical plasma membrane
localization of most GPCRs. These results were verified using an antibody directed
against GPR30 in MCF7, SKBR3, MDA-MD-231, JEG, and HEC50 cells endogenously
expressing GPR30. Using E2-Alexa633 as the tracer, E2 displayed a Ki of 6.6nM in
GPR30-transfected COS cells, similar to the Kd determined for [3H]E2 by Thomas et al.
Additionally, E2-Alexa546 colocalized with intracellular pools of GPR30-GFP in
permeabilized cells, but not in unpermeabilized cells, when imaged using confocal
fluorescence microscopy. These results suggest GPR30 is present on the endoplasmic
reticulum and Golgi apparatus, where it is able to bind E2 (37). These two reports
provided the first evidence of E2 binding to GPR30, and GPR30 was subsequently
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renamed G protein-coupled estrogen receptor 1 (GPER) by the International Union of
Basic and Clinical Pharmacology.

1.3.3 GPER Signaling
GPER activates rapid non-genomic signaling resulting in epithelial cell
proliferation and motility. Filardo and colleagues demonstrated GPER-dependent PERK1/2 was blocked by the EGFR inhibitor tyrphostin AG 1478 (AG 1478), suggesting
GPER signals via EGFR transactivation. P-ERK1/2 was also inhibited by Src family
tryrosine kinase inhibitors, PP2, and heparin-bound-EGF (HB-EGF)-neutralizing
antibodies. Furthermore, pertussis toxin and a Gβγ-sequestering peptide also inhibited
GPER-dependent ERK1/2 activation (35). Therefore, it was concluded that GPER
signaled through Gβγ-dependent Src activation ultimately resulting in transactivation of
the EGFR following cleavage of proHB-EGF by matrix metalloproteinases (MMPs).
Integrin α5β1 activation and Shc recruitment were subsequently determined to be
required for EGFR transactivation (38). Although GPER induces P-ERK1/2 downstream
of EGFR, it also inhibits P-ERK1/2 via cAMP production resulting from Gαs activation.
This dual action of GPER tightly regulates ERK1/2 activation, which ensures the potent
actions of ERK1/2 are not sustained (39).
Further investigation of the signaling downstream of GPER-dependent EGFR
transactivation revealed E2-stimulated intracellular Ca++ release as well as activation of
phosphatidylinositol 3-kinase (PI3K). COS7 cells exogenously expressing GPR30 were
loaded with the calcium sensitive dye Indo-1AM and stimulated with E2 in the presence
and absence of pertussis toxin and AG 1478. E2-stimulated intracellular Ca++
mobilization was sensitive to pertussis toxin and AG 1478, demonstrating Ca++
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mobilization occurs downstream of GPER-dependent EGFR transactivation. To
investigate PI3K activation, GPER-GFP and the PH domain of AKT fused to monomeric
red fluorescent protein (PH-mRFP) were expressed in COS7 cells. Cells were stimulated
with tamoxifen, E2, and E2 in the presence of AG 1478, pertussis toxin, and the PI3K
inhibitor, LY294002. The localization of PH-mRFP was analyzed in GPER-expressing
cells by confocal microscopy. In unstimulated cells, PH-mRFP was dispersed throughout
the cell. However, upon stimulation with E2 or tamoxifen, PH-mRFP translocated to the
nucleus. AG 1478, pertussis toxin, and LY294002 inhibited the nuclear translocation of
PH-mRFP (37). Therefore, E2 stimulated the activation of nuclear PI3K through GPERdependent transactivation of EGFR (Figure 1.4).
Downstream of GPER-initiated rapid signaling, transcription of genes such as
Bcl-2, cyclin D, and c-fos is regulated, enhancing cell proliferation and survival (40‐42).
Many of the genes indirectly regulated by GPER are involved in proliferation and cell
survival, as would be expected downstream of PI3K and MAPK signaling. Therefore,
while E2-dependent effects are often separated into rapid signaling and long-term
genomic actions, the lines can become blurred as rapid signaling modulates gene
transcription.
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Figure 1.4 GPERmediated signaling. GPER stimulated by E2 activates heterotrimeric
G proteins leading to Src activation. Src recruites Shc and activates matrix
metalloproteinases (MMPs). MMPs cleave cell surface‐bound heparin‐bound EGF causing
the autocrine and paracrine activation of EGFR. EGFR activates MAPK and PI3K and
enhances calcium mobilization. MAPK and PI3K mediate rapid non‐genomic effects in
the cytoplasm and translocate to the nucleus to modulate transcription. GPER
stimulation also activates adenylyl cyclase to produce cyclic AMP (cAMP), which inhibits
EGFR‐mediated MAPK activation, thereby regulating MAPK signaling.
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1.3.4 GPER Ligands
Using cell systems that either express GPER but lack ERα/β or by exogenously
expressing GPER in cells that lack all three estrogen receptors, GPER has been
characterized as an E2 receptor. However, because the classical ERs, specifically ERα,
are also able to activate rapid E2 signaling, it is essential to determine GPER-specific
physiologic outcomes (43). Since GPER and ERα share many of the same ligands,
including E2, ICI 182,780, and tamoxifen, it is difficult to study the effects of GPER in
isolation. Therefore, virtual screening of a 10,000 chemical compound library was
followed by flow cytometric binding assays to discover GPER-selective ligands (44).
COS7 cells were transiently transfected with exogenous estrogen receptors and binding
of E2-Alexa633 was measured by flow cytometry. The cells were preincubated with the
prospective compound followed by addition of E2-Alexa633 and assayed for inhibition
of E2-Alexa633 binding. One compound, a substituted dihydroquinoline, was determined
to selectively inhibit E2-Alexa633 binding in COS7 cells expressing GPER and has been
named G-1 (GPR30-specific compound 1) (Figure 1.5). The Ki of G-1 for GPER was
determined to be 11 nM. To determine the activity of G-1, intracellular Ca++ mobilization
and PI3K activation were analyzed. In COS7 cells transiently transfected with ERα, ERβ,
or GPER, G-1 was able to initiate intracellular calcium release only in cells expressing
GPER, whereas E2 initiated Ca++ release in cells expressing any of the three known E2
receptors. Similarly, while E2 induced PI3K activation in COS7 cells expressing ERα,
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ERβ, or GPER, G-1 was only able to induce PI3K activation in cells expressing GPER
(44). Therefore, G-1 is classified as a highly selective-GPER agonist and has been
widely used to examine the contribution of GPER to E2 signaling and physiology.
Following the discovery of G-1, it became clear a GPER-selective antagonist
would enhance the understanding of GPER-dependent E2 signaling, especially in
situations where all three ERs were present. Virtual screening and synthetic chemistry
were used to identify G-1-like compounds, particularly those lacking potential hydrogenbonding moieties. Candidate compounds were assessed to determine if they inhibited E2
mediated Ca++ mobilization in GPER-expressing cells. G15, a compound similar in
structure to G-1, except that it lacks the ethanone moiety, was determined to have
antagonistic properties and competitively bound GPER with a Ki of about 20nM (Figure
1.5). G15 displayed very weak affinity for ERα and ERβ with a Ki >10µM. Further
testing revealed that G15 inhibited GPER-mediated Ca++ mobilization, PI3K activation,
and in vivo uterine proliferation. Although 1 µM G15 was unable to activate ERαmediated PI3K activation, it bound weakly to ERα and ERβ at 10 µM and at that
concentration was able to activate transcription of an ERE reporter, at about 20% the
maximal efficacy of E2 (45). Because G-1 lacked this activity, even at 10µM
concentrations, it was hypothesized that the additional steric hindrance due to the
ethanone moiety of G-1 prevented access and/or binding to the ligand-binding pocket of
ERα and ERβ. Therefore, to mimic the steric bulk of G-1, but to prevent possible
hydrogen bonding of the keto group to GPER, resulting in activation, a G-1 analog was
synthesized in which the keto group was converted to a methyl group. The compound
synthesized was named G36 (Figure 1.5) (46). G36 did not bind the classical ERs or
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activate ERE-dependent transcription at 10µM. However, like G15, it was able to
antagonize GPER-mediated Ca++ mobilization and PI3K activation, demonstrating G36 is
a more selective GPER antagonist than G15 (46). Thus, there are now three GPERselective ligands that together have greatly enhanced our understanding of GPER
biology.
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Figure 1.5 GPERselective ligands. Chemical structures of GPER‐selective agonist (G‐1) and
antagonists (G15 and G36).
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1.4 Estrogen Biology
E2 is the main female sex steroid and plays a role in regulating female
reproduction and the development of secondary sex characteristics. Serum E2 levels are
low in females until the onset of puberty, at which time E2 levels rise and initiate breast
development, widening of the pelvis, and increased fat deposition (12). During
reproductive years, spikes in E2 trigger ovulation, and coordinated changes in E2 and
progesterone levels stimulate endometrial proliferation and thickening to prepare the
uterus for possible implantation of a fertilized egg. If implantation does not occur, E2 and
progesterone levels return to baseline and the endometrium is shed producing menses
(12). Successful implantation preserves high E2 levels, which are sustained throughout
pregnancy to maintain the endometrium and cause vasodilation to enhance blood flow to
the fetus, among other actions (47, 48). Although the role of E2 is best described in
female reproduction, it affects a wide variety of physiologic systems in the male and
female. E2 is neuroprotective (49), maintains bone density (50, 51), reduces the
incidence of cardiovascular disease (52), and modulates the immune system (53). It is
also

involved

in

male

reproduction

by

promoting

testicular

development,

spermatogenesis, and sperm maturation (54‐56). These diverse effects of E2 can be
attributed to the classical ERs and GPER.

1.4.1 E2 in Breast Development
The mammary gland is composed of branching ductal structures embedded
in the mammary fat pad. The ducts are made up of a single layer of luminal
epithelial cells surrounded by a layer of myoepithelial cells. In mammals,
mammary gland development begins during embryogenesis, and at birth, males
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and females have developed similar rudimentary ductal structures in the mammary
fat pad (57). The development of the rudimentary mammary gland is unaffected in
ERα, ERβ, ERα/β, and GPER knockout mice, suggesting that the initial
development of the mammary gland is E2-independent (58). In females, with the
onset of puberty, the ducts grow and branch in response to E2 until they reach the
distal end of the mammary fat pad (59). However, the mammary gland is not fully
mature until the third stage of growth during pregnancy and lactation when
branching again increases and the luminal epithelial cells produce and secrete
milk. Following cessation of milk production, involution occurs, demarcated by
apoptosis of the epithelial cells, which are replaced by adipocytes (60).
About 15-25% of normal breast epithelial cells express ERα, while the
majority of luminal epithelial and myoepithelial cells express ERβ. The mammary
gland of ERα knockout mice does not develop beyond the rudimentary ducts
formed during embryogenesis (61). Using an orthotopic transplant model, it was
determined that ERα is required in both the luminal epithelial cells and the stroma.
However, proliferating mammary cells are ERα negative, indicating E2 stimulates
proliferation through a paracrine mechanism (62). In contrast ERβ and GPER
knockout mice have no defects in peripubertal mammary gland development (58).

1.5 Breast Cancer
Breast cancer is the most common type of cancer among women, excluding
nonmelanoma skin cancer. Data gathered from 2006-2008 demonstrates women have a
1:8 lifetime risk of developing breast cancer, with probability dramatically increasing
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after the age of 40. Although early detection and improved treatment options have
decreased the mortality rate, breast cancer remains the second most common cause of
cancer-related death in women as about 40,000 women die of breast cancer each year in
the United States (63). Breast cancer is an exceptionally heterogeneous disease, and thus
tumors are stratified into groups to predict prognosis and response to treatment.

1.5.1 Breast Cancer Classifications
Many parameters have been used to classify breast cancer and patients with breast
cancer including clinical, histologic, immunopathologic, molecular, and genomic
markers. More recently, researchers have become interested in generating clinically
assessable micro- and macroenvironmental markers. Currently, clinical parameters
(patient age, tumor size, and lymph node status) are used in conjunction with histologic
and immunopathologic information to determine patient prognosis and predict response
to treatment (64, 65). Histologic subtypes of breast cancer are based on cytologic and
architectural features. In situ carcinoma describes a tumor that has not invaded through
the basement membrane. These tumors are further divided into ductal and lobular
carcinoma in situ (DCIS and LCIS, respectively) with a higher prevalence of DCIS than
LCIS. Histologically, LCIS is highly uniform whereas DCIS is more heterogeneous and
further sub-classified as comedo, cribiform, micropapillary, papillary, or solid (65).
Invasive or infiltrating carcinoma describes tumors that have invaded into the
surrounding tissue through the basement membrane. These tumors are sub-classified as
tubular, ductal lobular, invasive lobular, infiltrating ductal, mucinous (colloid),
medullary, or papillary carcinoma (66). Infiltrating ductal carcinoma accounts for about
75% of invasive breast carcinoma cases and invasive lobular carcinomas account for
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another 10% of cases, making up 85% of invasive tumors (67). Infiltrating ductal
carcinoma is further classified into well differentiated, moderately differentiated, and
poorly differentiated groups based on nuclear pleomorphism, glandular or tubule
formation, and mitotic index (Figure 1.6A) (65).
While histological classification is useful to determine prognosis and how well a
tumor may respond to chemotherapy, it does not aid in determining how well a patient
will respond to molecularly targeted therapies. Therefore, in combination with
histological classification, tumors are further classified based on immunopathologic
markers. Presently, the most common markers include ERα, progesterone receptor (PR)
and HER2, detected by immunohistochemistry (IHC) (64). Ambiguous IHC results for
HER2 are subjected to fluorescence in situ hybridization (FISH) to evaluate the tumor for
HER2 gene amplification (68). PR and ERα are typically correlated as ERα drives the
expression of PR. ERα+ tumors are correlated with a better outcome and can be targeted
by endocrine therapies including ERα inhibitors and aromatase inhibitors (64).
Additionally, patients with PR+/ERα- tumors are often treated with endocrine therapy as
PR expression serves as evidence for ERα activity (69). HER2+ tumors make up 15-20%
of breast cancer cases and previously predicted poor patient outcome because HER2
drives tumor proliferation and aggressiveness (69). However, upon the discovery of
HER2-targeted therapies, mortality decreased by 30-35% so now HER2+ tumor predicts
a treatable patient population (70). Currently, triple negative tumors (PR-/ERα-/HER2-)
are associated with poor outcome, and there are no successful targeted treatment
strategies for triple negative disease (71). These three markers also exemplify the
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intratumoral heterogeneity that exists in breast cancer because only a small percentage of
cells may express these receptors.
More recently, molecular classifications of breast cancer have been identified
based on microarray data obtained from patient samples and are designated as the
intrinsic molecular subtypes of breast cancer (72, 73). The molecular subtypes include
claudin low (ERα-, claudin3/4/7low, vimentin+, E-cadherinlow, zeb1+), basal-like (ERα-,
PR-, HER2-, cytokeratin 5/14+, EGFR+), HER2-enriched (HER2+, ERα-), normal breastlike (adipose tissue gene signature+), luminal A (ERαhigh, HER2low), and luminal B
(ERαlow,

HER2low,

proliferationhigh)

(Figure

1.6B)

(74).

The

widely

used

immunopathologic markers group cancers based on the expression of a few proteins,
whereas the intrinsic molecular subtypes are able to further stratify cancer subtypes based
on the expression of hundreds of mRNAs. However, this strategy is too expensive to be
routinely implemented clinically. Therefore, researchers have narrowed down the number
of genes required to make molecular profiling of patient samples clinically feasible.
PAM50, a panel of 50 genes detected by RT-PCR, is a cost effective substitute for
microarray analysis. PAM50 in combination with clinical parameters has a 94%
sensitivity with a 97% negative predictive value when used to predict pathological
complete response to treatment (75). Although PAM50 and similar gene expression
signatures have been implemented in the clinic, many physicians still rely on
immunohistochemical analysis of ERα, ERβ, and HER2 to determine prognosis and
treatment (76). The more information gained about individual breast cancers, the more
difficult it is to group breast cancers into subtypes, demonstrating the need for
personalized medicine. Many scientists have suggested using the intrinsic molecular
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subtypes as tangible points on a breast cancer spectrum to help stratify and successfully
treat patients.
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Figure 1.6 Breast cancer classifications. A. Histopathological classification of
breast cancer, defined by tissue morphology. B. Intrinsic molecular subtypes of
breast cancer, determined by gene microarray.
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1.5.2 Breast Cancer Microenvironment
Many studies analyzing breast carcinogenesis focus on the epithelial tumor cells
and ignore the stroma or tumor microenvironment. However, in a study by BarcellosHoff, cleared mammary fat pads were irradiated before transplantation of nontransformed epithelial cells. The irradiated stroma caused transformation of the epithelial
cells resulting in tumor development, exemplifying the importance of the
microenvironment in inhibiting tumor development (77). More physiologically relevant
is the effect of chronic inflammation on tumor formation, which causes infiltration of
immune cells, production of reactive oxygen species, and fibroblast activation leading to
epithelial dysregulation and tumor formation (78‐81). While stromal alterations are able
to initiate the development of breast cancer, precancerous and cancerous cells also
modify the microenvironment, further enhancing tumor survival, growth, and the ability
to metastasize. Stromal alteration can enhance the release of growth factors, increase
blood supply to the tumor, or change the make-up of the ECM to aid in migration and
metastasis (82‐84). However, these alterations can also cause genetic and epigenetic
changes in the epithelial cells making the tumor more aggressive (82). In this manner,
the tumor cells and microenvironment form a feedback loop to augment tumor
progression.
Infiltrating immune cells, specifically macrophages, have been demonstrated to
enhance tumorigenesis (85). Macrophages are extremely plastic cells that respond to
multiple stimuli produced during injury and infection. Three populations of activated
macrophages have been described, namely classically activated, regulatory, and wound
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healing. Macrophages are often activated along a spectrum, rarely fitting neatly into any
one category (86). Typically, macrophages become classically activated during infection
when pro-inflammatory cytokines such as interferon-γ (INFγ) and tumor necrosis factor
(TNF) are produced. When classically activated, macrophages are capable of clearing
invading pathogens and inhibiting tumorigenesis. Wound healing macrophages are
generated after injury in response to IL-4 and produce ECM components such as
collagen, while secreting very low levels of pro-inflammatory cytokines. Regulatory
macrophages develop in response to glucocorticoids or IL-10 and secrete IL-10, which
dampens proinflammatory immune responses (86). Tumor associated macrophages
(TAMs) are polarized by factors in the tumor microenvironment and fall on the spectrum
between wound healing and regulatory macrophages (86). TAMs secrete IL-10 and
inhibit the production of inflammatory cytokines, thus protecting tumor cells from attack
by the immune system (87). TAMs also aid in angiogenesis, remodel the ECM, and
produce growth factors (88, 89). Collectively, the actions of TAMs enhance tumor
growth and metastasis.
E2, which is present in high concentration in breast tumors, is able to polarize
macrophages. Although the actions of E2 on macrophages can be ambiguous, many
reports demonstrate a decrease in proinflammatory cytokine release by macrophages in
the presence of E2 through activation of ERα and GPER (90, 91). Therefore, E2 in the
tumor microenvironment may play a role in reeducating macrophages and decreasing
their anti-tumoral response.
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1.5.3 ERα in Breast Cancer
Prolonged exposure to estrogen, defined as early menarche and late menopause,
or high serum E2 levels increases the risk of developing breast cancer. A receptorindependent mechanism has been described where estrogen metabolites, specifically
catechol-estrogens, can form DNA adducts leading to mutagenesis and the development
of cancer (92). A non-transformed, ERα- breast epithelial cell line, MCF10F, was
malignantly transformed when exposed to physiologic concentrations of E2 due to
exposure to estrogen metabolites (93). However, an ERα-dependent mechanism has also
been proposed whereby ERα stimulation by E2 causes increased breast cell proliferation
providing increased opportunity for development DNA mutations. The mutations are
unable to be effectively repaired because DNA repair machinery is less efficient in
rapidly dividing cells (94). Crossing ERα knockout mice with mice that overexpress the
oncogene Wnt-1 provided in vivo evidence for ERα initiating breast cancer. In ERα/Wnt-1 mice, 50% of tumors occurred by 11 months compared with 5 months for the
ERα+/Wnt-1 mice, suggesting ERα contributes to breast cancer development (95). In
addition, inhibiting ERα with tamoxifen or raloxifene is a successful breast cancer
prevention strategy in pre-menopausal women (96‐98).
E2 also promotes the growth and distant metastasis of existing breast tumors
through stimulation of ERα. E2-dependent tumor growth was first clinically observed in
1896 when oophorectomy dramatically decreased the size of breast tumors. In more
recent years, the use of partial or full ERα antagonists such as tamoxifen, raloxifene and
ICI-182,780 have been successful therapies in ERα+ breast cancer, decreasing recurrence
rates and increasing disease free survival (96‐98). Approximately 70% of human breast
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cancers are ERα+ and the majority responds to endocrine therapy that inhibits either ERα
or the production of E2 by aromatase (59, 99). ERα-dependent growth is not only
observed in premenopausal women, but also in postmenopausal women despite low
levels of circulating E2. E2 in postmenopausal women is produced from extra-ovarian
sites, particularly adipose tissue, making increased body fat a risk factor for breast cancer
(100). Additionally, the intratumoral concentration of E2 in postmenopausal women with
breast cancer are 20-fold higher than circulating E2, due in part to the production of E2
by tumor cells expressing high levels of aromatase as well as increased binding to ERα
(101, 102). Intratumoral E2 targets ERα in the nucleus, regulating genes to increase
proliferation and decrease apoptosis. As opposed to normal breast tissue, in tumors,
stimulation of ERα drives proliferation of the cells expressing ERα, demonstrating a
deviation from normal E2-induced paracrine signaling (103). An extranuclear ERαdependent pathway has been reported that activates kinase cascades, such as the MAPK
cascade, thereby increasing cell proliferation and decreasing cell death (104). The
extranuclear signaling has also been implicated in cytoskeletal reorganization resembling
alterations involved in metastasis (105). Therefore, it is well established that ERα
enhances breast tumor growth as well as progression to metastasis.

1.5.4 Anti-Estrogen Treatment of Breast Cancer
Many cases of breast cancer are detected while they are still contained in the
breast, meaning there is no detectable spread of disease to the draining lymph nodes or
distant sites. Therefore, initial treatment primarily involves surgical removal of the tumor.
However, after removal of the tumor, 50% of women die from dormant micrometastases
undetectable at the time of diagnosis (106). Consequently, adjuvant therapy is initiated
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after the removal of the primary tumor to eradicate these micrometastases (107). The
type of adjuvant therapy depends on the histological grade of the tumors as well as the
expression of ERα and HER2. HER2+ tumors are treated with one year of anti-HER2
therapy subsequent to or in combination with standard chemotherapy (108). If the tumor
is ERα+, endocrine therapy is initiated (109). As of 2010, the American Society of
Clinical Oncology suggests premenopausal women with ERα+ cancer receive tamoxifen
for 5 years as aromatase inhibitors (AIs) are contraindicated in premenopausal women. If
the patient is postmenopausal after 5 years of treatment with tamoxifen, then 5 years of
additional treatment with AIs is recommended (110, 111). In postmenopausal women,
the use of combination treatment with tamoxifen and AIs is recommended, but the exact
order and length of treatment is debated. AIs can be used initially as an adjuvant therapy
for 5 years or AI treatment can be initiated following treatment with tamoxifen. The
length of tamoxifen treatment before the initiation of AIs is also debated. The guidelines
state AIs can be initiated after 2-3 years of tamoxifen or after 5 years of tamoxifen
treatment (109). There are many examples of treatment paradigms, but all guidelines
recommend the use of AIs alone or in combination with tamoxifen for treatment of breast
cancer in postmenopausal women.
Tamoxifen is a selective estrogen receptor modulator (SERM) that inhibits the
AF2 domain of ERα, but not the AF1 domain. In the breast, where ERα activity is
primarily due to AF2 domain activity, tamoxifen acts as an antagonist (112). However,
in the bone, cardiovascular system, and endometrium tamoxifen acts as an agonist, due to
the recruitment of different coregulators (113). Consequently, tamoxifen is beneficial in
the bone, reducing the occurrence of osteoporosis, and can also be cardioprotective
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(114). Although tamoxifen treatment can cause proliferation and even carcinogenesis in
the endometrium in postmenopausal women, the benefits for breast cancer treatment
outweigh the risks (115). A meta-analysis of clinical trials comparing adjuvant
tamoxifen treatment for 5 years to no adjuvant tamoxifen treatment determined treatment
of patients with ERα+ cancer reduced the rate of recurrence by 39%. This effect was
maintained at least ten years after cessation of tamoxifen treatment in both pre- and
postmenopausal women (116).
While tamoxifen targets ERα, AIs inhibit the enzyme that produces E2. The
comparison of five years of AI or tamoxifen treatment in postmenopausal women
determined AIs decrease the risk of recurrence by an additional 5% as compared with
tamoxifen, but the overall survival is not different (117). However, switching to an AI
after 2-3 years of tamoxifen for a total of 5 years of treatment decreased the risk of
recurrence and increased overall survival compared to tamoxifen alone for 5 years.
Therefore, there are many treatment combinations for postmenopausal women with ERα+
breast cancer that continue to be evaluated by randomized clinical trials (109).

1.5.5 GPER in Breast Cancer
The role of E2 in breast cancer has been classically ascribed to ERα. However,
accumulating evidence suggests that GPER may also affect the growth and progression of
breast cancer. GPER transactivates EGFR leading to activation of MAPK and PI3K
cascades (35). Both of these signaling cascades have been implicated in carcinogenesis
due to the ability to increase cell proliferation and survival. GPER stimulation in MCF7
(ERα+, GPER+) and SKBR3 (ERα-, GPER+) increases cell proliferation through
transactivation of EGFR (35). GPER stimulation in these cell lines also upregulates the
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mRNA and protein expression of the proto-oncogene c-fos (41). Additionally, a study
using SKBR3 cells demonstrated E2 stimulation of GPER increases the expression of
connective tissue growth factor (CTGF), required for the migration of SKBR3 cells
(118). These studies suggest that, similar to ERα, GPER stimulation results in cell
proliferation and metastasis that could play a role in breast cancer in vivo. In 2006, a large
cohort of breast cancer samples was examined for the expression of GPER.
Approximately 60% of the samples expressed GPER, with roughly 50% of ERα- tumors
expressing GPER, indicating an intact E2 signaling pathway in many ERα- tumors. This
study also demonstrated increased tumor size and presence of distant metastases
correlated with increased GPER expression (119).
Approximately 50% of patients develop resistance to tamoxifen and relapse with
a more aggressive cancer phenotype. Many mechanisms of resistance have been
described, but a relatively new proposed mechanism is that activation of GPER by
tamoxifen enhances tumor proliferation thereby negating its actions on ERα (120).
MCF7 cells were cultured in tamoxifen to induce tamoxifen resistance. It was
demonstrated that GPER-dependent AKT activation partially mediated the observed
tamoxifen resistance (120). Additionally, a study examining breast cancer samples
comparing patients treated with tamoxifen to those who were not administered tamoxifen
revealed that GPER expression was negatively correlated with relapse-free survival and
independently predicts a poor relapse-free survival in patients who received tamoxifen as
a monotherapy in an adjuvant setting (121). These studies suggest GPER may be a good
therapeutic target in patients with ERα- cancer as well as in patients treated with
tamoxifen.
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1.6 PyMT Model of Breast Cancer
Multiple transgenic mouse models of breast cancer are available to study the in
vivo effects of a specific treatment or a protein of interest (60, 122). Many murine
models of breast cancer express oncogenes under the control of the mouse mammary
tumor virus (MMTV) promoter, which is primarily activated in mammary tissue.
Common models of breast cancer include HER2/neu overexpression, P53 knockout, and
polyoma middle T antigen (PyMT) expression (60).
PyMT is derived from the murine polyoma virus that initiates tumor formation in
multiple tissues in infected mice. Three early viral proteins are present in tumor cells and
are named large, middle, and small tumor antigen (LT, MT, and ST respectively). All
three proteins are essential in the replication of the viral genome and have been
implicated in the transformation of epithelial cells (123). However, the MT antigen
(PyMT) is necessary and, in many cases, sufficient for cell transformation. PyMT does
not have intrinsic catalytic activity. Instead, it associates with the cell membrane through
a hydrophobic region in the C-terminus, where it acts as a scaffold for cellular signaling
proteins including Src family kinases, protein phosphatase 2A (PP2A), Shc, PI3K, and
PLC-γ (124). Through binding to these cellular proteins, their normal spatio-temporal
regulation is disrupted, leading to cell transformation and tumor development.
The MMTV promoter restricts PyMT expression primarily to the female
mammary tissue although low levels are detected in the salivary glands, ovaries,
epididymis, and seminal vesicles. However, tumor formation is generally restricted to the
female mammary gland. Multifocal lesions first develop near the teat and extend into the
mammary gland (123). There are four stages of tumor development in MMTV-PyMT

35

mice that histologically resemble human tumors of the same grade. First, the mice
develop hyperplasia (4 weeks of age) followed by adenoma/mammary intraepithelial
neoplasia (6-8 weeks of age), early carcinoma (8-12 weeks of age), and late carcinoma
(10-14 weeks of age). As the tumors develop, ERα and PR expression are lost and ErbB2
(HER2/neu) expression increases, suggesting more aggressive disease (125). During late
stage carcinoma, 94% of mice develop lung metastases, which is dependent on the
recruitment of macrophages to the tumor (126). Because this model mimics human
tumors and metastasizes to the lung, it is an excellent model to use to examine the role of
proteins, such as GPER, in the development and progression of breast cancer.

1.7 Project Rationale
E2 drives normal and neoplastic breast cell proliferation and survival. These E2
effects have traditionally been ascribed to the classical ER, ERα (6, 59). However, new
evidence suggests that the non-classical E2 receptor, GPER increases proliferation of
breast cancer cells in vitro (118).
ERα is a nuclear steroid receptor that typically modulates gene expression of
target genes, occurring over several hours. However, E2 also mediates rapid non-genomic
cellular responses including activation of ERK1/2, PI3K, and Ca++ mobilization. Some of
these rapid responses can be attributed to E2 stimulation of mERα to associate with G
proteins initiating downstream signaling cascades (25). In cells lacking ERα and the
other classical ER, ERβ, rapid E2 signaling still occurs (28). This ERα-independent
rapid signaling has now been attributed, at least in part, to GPER. Growing evidence in
vitro demonstrates a role for GPER in E2-mediated cell proliferation, survival, and
migration, all hallmarks of tumor progression and aggressiveness. GPER expression in
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patient samples has been correlated with increased tumor size, distant metastasis, and
recurrence of breast cancer (119). Further, patients treated with tamoxifen have an
increased risk of recurrence if their tumors express GPER (121). In breast tissue,
tamoxifen inhibits ERα; however, tamoxifen activates GPER, which could contribute to
tamoxifen resistance (35, 36). Furthermore, approximately 50% of ERα- tumors maintain
GPER expression, suggesting a partially intact E2 signaling pathway that could drive
proliferation (119). Collectively, this data suggests GPER may play a role in enhancing
breast cancer aggressiveness, although strong in vivo evidence does not exist. Therefore,
it is important to establish GPER as a contributor to breast cancer initiation and
progression to determine if it could represent a novel therapeutic target.

1.8 Hypothesis and Specific Aims
Although GPER has been associated with aggressive breast cancer and enhances
breast cancer cell proliferation, in vivo evidence for GPER enhancing breast cancer is
lacking. We hypothesize GPER augments breast cancer growth and metastasis in the
MMTV-PyMT in vivo model of breast tumorigenesis.

1.8.1 Specific Aims
Aim 1. Determine the significance of GPER in mammary tumor growth and
progression in the MMTV-PyMT murine model of mammary carcinogenesis
1.1 Elucidate tumor size, grade and receptor status from GPER WT and KO
MMTV-PyMT mice
1.2 Assess lungs from GPER WT and KO MMTV-PyMT mice for the presence of
metastases
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Aim 2. Analyze the disparate effects of GPER expression in the tumor parenchyma
and microenvironment in the MMTV-PyMT model
2.1 Determine if GPER expression in the tumor microenvironment affects growth
and metastasis of orthotopically translplanted GPER WT tumors
2.2 Evaluate the effects of GPER expression in the tumor microenvironment on
the growth and metastasis of orthotopically translplanted GPER KO tumors
2.3 Assess the role of GPER expression in macrophages in tumor growth and
metastasis in orthotopically translplanted GPER WT tumors
Aim 3. Assess the consequences of GPER-targeted compounds on the progression of
tumors in the MMTV-PyMT model
1.1 Analyze the size and grade of tumors from MMTV-PyMT mice treated with
GPER-selective compounds in the presence and absence of E2
1.2 Assess lungs from treated MMTV-PyMT mice for the presence of metastases
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CHAPTER 2
GPER REGULATES MAMMARY TUMORIGENESIS
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2.1 Abstract
17β-estradiol (E2) is known to enhance breast cancer development and tumor
growth through the activation of ERα. The discovery that ERα stimulates proliferation in
breast tumor cells led to major advances in breast cancer treatment, drastically improving
the prognosis for women with ERα+ breast cancer. However, patients whose tumors do
not express ERα or become resistant to treatment have fewer options and rely on
chemotherapy, which has many side-effects. This suggests targeting ERα alone is not
sufficient to eliminate breast cancer. The discovery of G protein-coupled estrogen
receptor (GPER) suggested an additional mechanism through which E2 could exert its
effects in breast cancer. Although there have been studies demonstrating a correlation of
GPER expression with larger tumors, increased incidence of distant metastasis and
recurrence in vivo as well as a proliferative role for GPER in vitro, in vivo evidence is
lacking . To determine the role of GPER in vivo, we intercrossed MMTV-PyMT (PyMT)
mice, a model of mammary tumorigenesis, with GPER knockout (KO) mice to determine
if GPER expression affects tumor size and progression. Tumor latency in PyMT mice
lacking GPER was not different than control mice. However, by 12-13 weeks of age,
GPER KO PyMT mice displayed smaller tumors with decreased proliferation and fewer
lung metastases. Therefore, we have provided the first in vivo evidence that GPER plays
a critical role in breast tumor growth and distant metastasis.
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2.2 Introduction
The steroid hormone, 17β-estradiol (estrogen, E2), is the primary female sex
hormone necessary for the development of secondary sexual characteristics in women
(12). Specifically, E2 mediates the development of breast tissue during puberty and
pregnancy by enhancing the proliferation of ductal epithelial cells (60). Similar to normal
development, E2 also promotes breast cancer by promoting the proliferation, migration,
and invasion of breast tumor cells both in vitro and in vivo (6). By inhibiting the activity
of the classical estrogen receptor ERα, many cancer-promoting effects of E2 in cultured
cells and mice are reduced; therefore, the actions of E2 in breast cancer have been
attributed almost exclusively to ERα (127‐129). Clinically, drugs administered to
women with breast cancer to block the production of estrogen or inhibit ERα, thereby
inhibiting E2 signaling, increase long-term survival (116). One of the most commonly
prescribed adjuvant treatments for breast cancer is tamoxifen, a selective estrogen
receptor modulator (SERM) that acts as an antagonist for ERα in the breast, inhibiting
tumor growth. Treatment with tamoxifen for 5 years after surgery decreases mortality by
31% (116). However, only patients with ERα+ tumors are eligible for treatment, and
many ERα+ tumors do not respond to tamoxifen or become resistant during treatment or
upon recurrence (103). While tamoxifen is a successful therapy, breast cancer is still the
second most common cause of cancer-related death in women in the US (63).
Additionally, aromatase inhibitors, which inhibit the production of E2, are more
efficacious for the prevention and treatment of beast cancer (117). These data suggest
inhibition of E2 signaling solely through ERα is insufficient and other E2 receptors may
be involved in the initiation and/or progression of breast cancer.
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G protein-coupled estrogen receptor 1 (GPER) is a novel estrogen receptor whose
role in breast carcinogenesis has yet to be determined. E2 stimulation of GPER activates
the MAPK cascade as well as PI3K, among other pathways, and increases proliferation of
breast cancer cells, suggesting it may play a role in one or more events of breast
carcinogenesis (35, 37, 41, 118, 130). A small number of retrospective studies have
examined the correlation between GPER expression in breast tumor samples and clinical
outcomes. A study of 361 breast cancer patients found GPER expression correlated with
increased size of the primary tumor and prevalence of distant metastasis (119). Another
study demonstrated an increased recurrence rate in GPER+ invasive ductal breast cancers
(131). Most recently, a study of invasive breast cancer samples demonstrated GPER
expression is an independent prognostic factor for decreased disease free survival in
patients treated with tamoxifen (121). While these studies suggest a role for GPER in
breast cancer, there is no direct experimental evidence that GPER plays a role in the
initiation and/or progression of breast cancer.
In this study, the MMTV-PyMT mouse was crossed with GPER KO mice to
investigate the contribution of GPER to breast carcinogenesis. MMTV-PyMT mice
express the polyoma middle T antigen (PyMT) primarily in mammary tissue, under
control of the mammary tumor virus (MMTV) promoter, resulting in the spontaneous
development of mammary tumors (123). PyMT mice develop hyperplastic lesions in
their mammary glands at 4 weeks of age that progress through the stages of adenoma,
early carcinoma and late carcinoma over the subsequent 8-10 weeks(125).
Histologically, PyMT tumors at each stage of development closely resemble similar stage
human tumors. Furthermore, changes in biomarkers during PyMT mammary tumor
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development are similar to human breast cancer as tumors progress from hyperplasia to
carcinoma, including loss of ERα, progesterone receptor and integrin β expression, and
an increase in the expression of Neu and cyclin D1 (125). Finally, analogous to human
breast cancer, early tumor growth in PyMT mice is E2-dependent, demonstrating the
PyMT model of mammary carcinogenesis to be a clinically relevant model of human
breast cancer (132).
In the present study, we demonstrate the presence of GPER promotes growth and
metastasis of late stage mammary tumors in PyMT mice, although we observed no
difference in tumor latency between GPER WT and GPER KO mice. As the tumors
progress, GPER KO mice displayed smaller tumors that exhibited a lower grade when
compared to GPER WT and GPER heterozygote (HET) mice. Consistent with decreased
size, GPER KO tumors displayed reduced proliferation compared to GPER WT mice.
Most importantly, GPER KO mice exhibited fewer lung metastases compared to GPER
WT mice. Taken together, these data demonstrate that silencing GPER decreases tumor
size and the number of distant metastases, suggesting that pharmacological inhibition of
GPER may represent a novel approach to reduce morbidity from breast cancer.

2.3 Methods
2.3.1 Mice. FVB/N-Tg(MMTV-PyVT)634Mul/J (MMTV-PyMT) mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). GPER KO mice were provided by Jan
Rosenbaum (Proctor & Gamble, Cincinnati, OH) and described previously (133). GPER
KO mice were backcrossed 10 generations onto FVB/NJ mice. GPER KO mice were
intercrossed with MMTV-PyMT mice to produce MMTV-PyMT mice that were wild
type (WT), heterozygous, or knock out (KO) with respect to GPER. Animals were
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housed at the animal research facility at the University of New Mexico Health Sciences
Center and maintained under a controlled temperature of 22–23 °C with a 12-h light, 12-h
dark cycle and fed a normal chow ad libitum. Tumors were allowed to grow until mice
were 7 weeks or 12-13 weeks old. Tumors were weighed as a measurement of tumor size.
Tumors and lungs were then resected, fixed in 4% PFA, and paraffin embedded. All
procedures were approved by and carried out in accordance with the institutional
protocols.

2.3.2 Ovariectomy. PyMT mice were anesthetized with isofluorane and placed in a
nose cone while lying on a 37 °C heating pad. Buprenorphine (0.1 mg/kg) was injected
prior to surgery. A small incision in the skin was made on the midline of the dorsal side
of the mouse just cranial to the hipbones. The skin was gently separated from the
underlying muscle to the left and right of the initial incision. An incision through the
muscle was made slightly lateral to the spine. The ovary was gently pulled through the
incision in the muscle with blunt forceps. While grasping the oviduct with forceps, a cut
was made just below the ovary to remove the ovary. The incision in the muscle was
closed using polydioxanone synthetic absorbable sutures (PDS* Plus, Ethicon) and the
skin incision was closed with 9 mm stainless steel tissue clips (ez CLIPS, Stoelting). The
mice were then allowed to recover in a 37 °C recovery chamber.

2.3.3 Tamoxifen Treatment. When PyMT mice were 4-weeks-old, a 60-day release
pellet containing tamoxifen (5 mg/pellet) (Innovative Research of America) was
subcutaneously implanted on the left dorsal side of the mouse just below the rib cage.
Tumors were resected at 12 weeks of age and weighed as a measurement of tumor size.

2.3.4 Relative Quantitation of PyMT gene expression. Mammary tumors from 10-
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week-old WT/PyMT and KO/PyMT mice were removed and stored in Trizol (SigmaAldrich). Tumors were homogenized using a Polytron tissue homogenizer. RNA isolation
was performed in Trizol using phenol-chloroform extraction according to the
manufacturers instructions. cDNA was created via reverse transcription of 1 µg RNA
with the iScript cDNA synthesis kit (BioRad) using the GeneAmp PCR system 9700
(Applied Biosystems, Inc.) according to manufacturers directions. Quantification of
PyMT mRNA relative to cytokeratin 18 mRNA was performed using Fast SYBR Green
(Molecular Probes) with the 7500 Fast Real-Time PCR System (Applied Biosystems,
Inc). A relative standard curve for each primer was created from a mixture of the sample
RNA extracted from the tumors with dilution values of 1.0, 0.25, 0.0625, and 0.0156. The
relative concentrations were expressed as arbitrary units and plotted against the logarithm
(base 20) of the dilution values. Linear regression was used to create a standard curve.
The standard curves were used to determine the relative amount of PyMT and cytokeratin
18 in each sample. The relative concentration of PyMT was then normalized to the
relative concentration of cytokeratin 18, which served as the endogenous control. The
primer sequences were: PyMT_Forward: 5’- CGG CGG AGC GAG GAA CTG AGG
AGA G -3’ Cytokeratin 18_Forward: 5’- CAA GTC TGC CGA AAT CAG GGA C -3’.

2.3.5 Tumor Histology. The largest tumors from 12-13 week old mice were sectioned
(5 µm) and stained with hematoxylin (Sigma-Aldrich) and Eosin (RICCA Chemical
Company). Tumor grade was determined by a veterinary pathologist, Donna Kusewitt,
DVM, PhD (The University of Texas MD Anderson Cancer Center). Grading PyMT
tumors has been previously described (125). Briefly, tumor grade is determined by tissue
architecture, degree of cellular atypia, and invasion into the surrounding stroma. Based
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on these parameters, tumors were assigned grades as follows: (1) Hyperplasia: Densely
packed acini filled or bridged by epithelial cells that have little to no cellular atypia.
There is no invasion into the surrounding stroma. (2) Adenoma/mammary intraepithelial
neoplasia (MIN): Increased proliferation of epithelial cells with acini mostly filled with
cells. There is minimal cellular atypia and no invasion is present. (3) Early carcinoma:
Florid proliferation with loss of acinar definition. There is moderate cellular atypia and
early stromal invasion. (4) Late carcinoma: Solid sheets of cells with very few or no acini
present. There is a high mitotic index consistent with increased proliferation. Marked
cellular atypia and pronounced stromal invasion are present. Sections were imaged with a
Nikon DS-Fi1 camera mounted on a Nikon Eclipse E400 microscope running NISElements software.
The extent of tumor necrosis was determined and categorized by the number and
size of necrotic areas. The score of necrosis is as follows: 1 = few small areas; 2 = few
larger areas or moderate number of smaller areas; 3 = extensive areas.

2.3.6 Immunostaining analysis. For immunostaining, 5 µm sections were
deparaffinized, rehydrated, permeabilized in PBS containing 0.01% Triton X-100, and
blocked in 3% normal goat serum (NGS) diluted in PBS plus 0.1% Tween-20 (PBS-T).
To evaluate the proliferation rate, microwave antigen retrieval was performed in
0.1 M sodium citrate (pH 6). Sections were stained overnight in a 1:100 dilution of the
anti-phospho-histone H3 (P-histone H3, phospho Ser10, EMD Millipore) followed by
detection with an anti-rabbit IgG antibody conjugated to Alexa 488 (Molecular Probes).
Coverslips were mounted with Vectashield mounting medium with DAPI (Vector
Laboratories). One random field from 3 sections was imaged with a Zeiss 200M Axiovert
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microscope using MetaMorph software. The number of P-histone H3 positive cells was
determined and normalized to the total number of cells per field. Apoptosis was evaluated
in the same manner, except the primary antibody was directed against cleaved caspase-3
(Asp 175) (Cell Signaling).
To detect ERα, microwave antigen retrieval was performed in TET buffer (10mM
Tris, 1mM EDTA, 0.05% Tween-20; pH 9) and endogenous peroxide activity was
quenched in 3% H2O2 before permeabilization. Sections were incubated overnight in a
1:100 dilution of anti-ERα antibody (MC-20) (Santa Cruz Biotechnology). The sections
were washed in PBS-T and incubated with anti-rabbit IgG antibody conjugated to
horseradish peroxidase (HRP) (Molecular Probes). 3,3'-Diaminobenzidine (DAB)
(Sigma-Aldrich) was used as the substrate to detect the presence of the HRP-conjugated
antibody. Coverslips were mounted with Permount mounting medium (Fisher Scientific).
Three random fields per section were imaged with a Nikon DS-Fi1 camera mounted on a
Nikon Eclipse E400 microscope running NIS-Elements software. The number of ERαpositive cells was determined and normalized to the total number of cells per field.

2.3.7 Lung Metastasis. Three 5 µm sections separated by 100 µm were prepared from
the lungs of 12-13 week old animals. Sections were deparaffinized, rehydrated, and
stained with H&E. Metastatic tumor foci present in the lung parenchyma are defined as a
tightly clustered group of 10 or more hematoxylin-positive cells that excludes eosinstained stroma. Total metastatic foci were counted in the three lung sections to determine
the extent of metastases.

2.3.8 Whole Mount. Number 4 mammary glands from 7 week old PyMT mice were
fixed in 4% PFA on stretched skin overnight at room temperature. The glands were
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removed from the skin, incubated overnight in 100% acetone to remove the fat, washed
in deionized water, and stained with carmine overnight. To generate carmine stain,
carmine alum lake (1g, Sigma-Aldrich) and aluminum potassium sulfate (2.5g, SigmaAldrich) were dissolved in 500 mL of distilled water by boiling for 20 min and then
filtered. After staining, the glands were washed in deionized water and dehydrated in
ethanol before storing them in methyl salicylate (Sigma Aldrich). Glands were imaged
with MoticCam 2300 running Motic software on an Olympus SZH dissection
microscope.

2.3.9 Statistical Analysis. Tumor size in ovariectomized and tamoxifen treated mice,
hyperplasia in 7 week glands, P-histone H3 positive cells, relative concentration of PyMT
RNA, ERα expression, and extent of lung metastasis were evaluated using two-tailed
student’s t-test with a p-value threshold of .05. Tumor size of WT/PyMT, HET/PyMT
and KO/PyMT mice was assessed using one-way ANOVA with Bonferroni correction for
multiple comparisons as a post-hoc test. Tumor grade and extent of necrosis were
analyzed using a two-tailed Fisher’s exact test with a p-value threshold of .05.
Correlation between ERα and tumor grade was assessed using Pearson’s correlation
analysis with a p-value threshold of .05.

2.4 Results
2.4.1 Ovariectomy and tamoxifen treatment reduce mammary tumor size.
Although GPER has been correlated with human breast tumor growth and metastasis, in
vivo studies examining the effects of GPER on breast cancer initiation, growth, and
progression have not been performed. To study the role of GPER in breast cancer, we
used the MMTV-PyMT (PyMT) model of mammary carcinogenesis, which has been
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reported to be an E2-responsive tumor model (132). To verify the E2-responsiveness of
tumor growth, PyMT mice were ovariectomized to remove the majority of circulating
estrogen. The size of tumors from ovariectomized mice was compared to tumors from
non-ovariectomized mice at 12 weeks of age. Mammary glands were palpated two times
per week to detect the presence of tumors. Both cohorts of mice developed tumors
between 7 and 8 weeks of age, suggesting there was no apparent effect of ovariectomy on
tumor latency. However, by 12 weeks of age, the tumors in the non-ovariectomized mice
were 5-fold larger than those in the ovariectomized mice (Figure 2.1A), indicating tumor
growth in PyMT mice is highly E2-responsive. Steroid hormones such as glucocorticoids,
progestins, androgens, and estrogens stimulate the MMTV promoter and increase the
expression of PyMT, whereas E2 is a weak activator of the MMTV promoter. Therefore,
to determine receptor-dependent E2 activity on tumor size, tamoxifen pellets were
subcutaneously implanted in 4-week-old PyMT mice. When mice were 12-weeks of age,
tumors were resected and weighed to determine tumor size. Tumors from mice treated
with tamoxifen were about 3.5-fold smaller than tumors from sham treated mice,
demonstrating the actions of E2 are receptor-dependent and not secondary to MMTV
promotion (Figure 2.1B). Additionally, ovariectomy was slightly more effective than
tamoxifen at decreasing tumor size indicating that ERα may not be the only estrogen
receptor regulating tumor growth. Because of its E2 responsiveness, this model is
appropriate for examining the role of GPER in mammary tumorigenesis.
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Figure 2.1 Estrogen enhances mammary tumorigenesis. A) PyMT mice were
ovariectomized at 3 weeks of age to remove the majority of circulating E2. Tumors
were resected and weighed as a measure of tumor size when mice were 12-weeks-old.
B) 60-day release tamoxifen pellets were subcutaneously implanted into 4-week-old
PyMT mice. Tumors were resected and weighed as a measure of tumor size when
mice were 12-weeks-old. Two-tailed Student’s t-test with a p-value threshold of .05
was used for statistical analysis.
* p < .05
** p< .01
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2.4.2 GPER deficiency does not affect the initiation of tumor formation or
early tumor growth. Male PyMT mice were intercrossed with female FVB mice
lacking GPER (KO) to generate male and female PyMT GPER heterozygous (HET) mice
(HET/PyMT). The male HET/PyMT and female HET/FVB mice were bred to produce
PyMT GPER WT, HET, and KO offspring (WT/PyMT, HET/PyMT, KO/PyMT,
respectively). In both WT/PyMT and KO/PyMT mice, tumors were palpable between 7
and 8 weeks of age, suggesting there is no difference in tumor latency. To assess
differences in early tumor development, whole mounts of the number 4 mammary glands
from 7-week-old WT/PyMT and KO/PyMT mice were stained with carmine to determine
the extent of hyperplasia. In Image J, a grid was overlaid on the whole mount images and
each box was evaluated for the presence of hyperplasia and epithelium (Figure 2.2A).
Total hyperplasia relative to total epithelium was 0.73 ± .05 for WT/PyMT and 0.64 ± .05
for KO/PyMT, demonstrating no statistical different (p > .05) (Figure 2.2B). To evaluate
if the lesions in WT/PyMT mice had extended farther into the mammary gland than in
KO/PyMT mice, indicating more advanced disease, hyperplasia distal to the lymph node
relative to total epithelium distal to the lymph node was determined. There was no
difference in the extent of hyperplasia distal to the lymph node between WT/PyMT (0.41
± .08) and KO/PyMT (0.34 ± .07) mice (p > .05) (Figure 2.2C). Next we addressed
proliferation in early tumors by staining number 2/3 mammary glands from 7-week-old
mice with an anti-phospo-histone H3 (P-histone H3) antibody, a marker of the M phase
of the cell cycle. We found no difference in the number of proliferating cells between
tumors from WT/PyMT (4/500 cells) and KO/PyMT (3/500 cells) mice (p > .05) (Figure
2.2D). Collectively, these data indicate GPER does not affect the development or early
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growth of mammary tumors.

52

Figure 2.2 Absence of GPER does not affect early tumor development. A) Whole
mounts of number 4 mammary glands from 7-week-old WT/PyMT and KO/PyMT
mice were stained with carmine to visualize hyperplasia. Using Image J software, a grid
was overlaid on the image, and each box was analyzed for the presence of hyperplasia
and normal epithelium. Hyperplasia was analyzed in the total gland and distal to the
lymph node. B) Quantification of total gland hyperplasia. The number of boxes
containing hyperplasia was normalized to the number of boxes containing total
epithelium, which is defined as hyperplastic and normal epithelium. C) Quantification
of hyperplasia distal to the lymph node performed in the same manner as in B. D)
Number 2/3 mammary glands from 7-week-old WT/PyMT and KO/PyMT mice were
stained with anti-phospho histone-H3 (p-H3) antibody to determine proliferation rate.
Statistical analysis was done using two-tailed Student’s t-test with a p-value threshold
of .05.
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2.4.3 Mammary tumor growth is reduced in the absence of GPER. Although
tumor development is unaffected by lack of GPER, tumors from older mice were
evaluated to determine whether GPER affects tumor progression. When mice were 1213-weeks-old, tumors were removed and weighed, as a measure of tumor size. There was
no difference between WT/PyMT and HET/PyMT tumor size; however, tumors from
KO/PyMT mice were 28% smaller than WT/PyMT mice (p < .05) (Figure 2.3A). To
verify the difference in tumor size was not indirectly caused by decreased expression of
PyMT mRNA in KO/PyMT mice, real time PCR was used to determine the level of
PyMT expression relative to cytokeratin 18, a marker of epithelial cells, in tumors from
WT/PyMT and KO/PyMT mice. No difference in the relative expression of PyMT RNA
between WT/PyMT and KO/PyMT mice was detected (p > .05), indicating differences in
tumor size were not indirectly caused by a decrease in PyMT expression (Figure 2.3B).
Because tumors in KO/PyMT mice were smaller than WT/PyMT tumors,
proliferation and apoptosis of the tumor cells were analyzed to determine the relative
contribution of each of these factors to overall tumor size. To evaluate the proliferation
rate, the number of cells positive for p-histone H3, which stains cells in the M phase of
the cell cycle, was determined and normalized to the total number of cells. Tumors from
KO/PyMT mice exhibited a 44% lower proliferation rate than tumors from WT/PyMT
mice (p < .05) (Figure 2.3C). Apoptosis was investigated using an antibody directed
against cleaved caspase-3 and similarly analyzed by microscopy. Although the positive
control exhibited cleaved caspase-3 expressing cells, the tumors did not display cleaved
caspase-3-positive staining regardless of the genotype. Therefore, WT tumors are larger,
in part, due to increase cell proliferation with no appreciable apoptosis.
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Figure 2.3 KO/PyMT mice have smaller tumors with decreased proliferation
compared to WT mice. A) Tumors from WT/PyMT and KO/PyMT mice were
resected and weighed at 12-13-weeks-old as a measure of tumor size. B)
Quantification of PyMT gene expression relative to cytokeratin 18 from 10-week-old
WT/PyMT and KO/PyMT mice. C) Images of P-histone-H3 (P-H3) staining on
tumors from 12-13-week-old mice. Blue represents DAPI staining and green
represents P-H3-positive cells. D) Quantification of P-H3-positive cells in tumors
from WT/PyMT and KO/PyMT mice. Statistical analysis was done using two-tailed
Student’s t-test with a p-value threshold of .05.
* p < .05
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2.4.4 GPER is associated with predictors of poor prognosis. To evaluate tumor
aggressiveness, sections of the largest tumor from WT/PyMT and KO/PyMT mice were
stained with H&E, analyzed to determine grade, and classified as either low-grade
(hyperplasia and adenoma) or high-grade (early and late carcinoma) (Figure 2.4A). The
majority of tumors from WT/PyMT mice lost acinar definition appearing as solid sheets
of cells, and had invaded through the basement membrane into the surrounding stroma,
indicative of carcinoma. In contrast, many tumors from KO/PyMT mice appeared to
maintain acinar structure, although the acini were filled with cells; in addition, fewer
tumors invaded through the basement membrane in the KO/PyMT mice. Based on
histological parameters, tumors were graded and it was determined that 90% of tumors
from WT/PyMT mice were carcinomas versus 50% of tumors from KO/PyMT mice,
demonstrating a strong trend for KO/PyMT tumors to exhibit a lower tumor grade than
WT/PyMT tumors (p = .056) (Figure 2.4B).
During tumor resection, it appeared that tumors from KO/PyMT mice contained a
smaller necrotic center that WT/PyMT mice. Because necrosis is an independent
predictor for poor prognosis, a smaller necrotic center suggests less aggressive tumors
(134). Necrosis was analyzed by evaluating the number and size of necrotic areas
categorized using a scale from 0-3 with 0 signifying a lack of necrosis and 3 representing
large and/or many areas of necrosis. The majority (78%) of tumors from WT/PyMT mice
were given a score of 2 or greater compared with 21% of tumors from KO/PyMT mice
receiving a score of 2 and no tumors from KO/PyMT mice receiving the highest score of
3 (Figure 2.4C). Thus, tumors lacking GPER exhibit fewer and smaller areas of necrosis
compared to tumors that express GPER. Taken together, these data suggest KO/PyMT
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tumors are less aggressive than WT/PyMT tumors.
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Figure 2.4 There is a trend for tumors from WT/PyMT mice to correlate with
predictors of poor prognosis compared with KO/PyMT mice. A) Representative
images of tumors from WT/PyMT and KO/PyMT mice stained with H&E. WT/PyMT
mice had little to no acinar definition, whereas acinar structures were present in many
tumors from KO/PyMT mice. B) Quantification of tumor grades from WT/PyMT
mice and KO/PyMT mice. C) Quantification of extent of necrosis for WT/PyMT and
KO/PyMT mice. Two-tailed Pearson’s chi-square test with a p-vale threshold of .05
was used for statistical analysis.
* p < .05
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2.4.5 ERα expression is unaffected by GPER deficiency. As ERα drives
proliferation in approximately 70% of human breast tumors and tamoxifen successfully
inhibited PyMT tumor growth, we considered that eliminating GPER could affect the
expression of ERα in the tumors of PyMT mice, thus indirectly affecting tumorigenesis
(59). To examine ERα expression, tumor sections from 7-week-old and 12-13-week-old
mice were stained and analyzed for the number of ERα-positive cells as well as staining
intensity. Tumors from 7-week-old mice displayed faint ERα staining in the
hyperplastic/adenomatous regions, and intense staining in the adjacent normal tissue,
suggesting that as tumors form ERα expression is lost (Figure 2.5A). The number of
ERα-positive cells in three random fields was determined and was not different between
tumor from 7-week-old WT/PyMT and KO/PyMT mice (Figure 2.5B). Tumors from 1213-week-old mice displayed faint ERα staining that was less intense than that of 7-week
hyperplastic tissue (Figure 2.5A). Consistent with 7-week staining, the number of ERαexpressing cells was not different between the two genotypes (Figure 2.5C). Thus,
manipulating the expression of GPER does not affect the expression of ERα. Because
patients with ERα-positive tumors have a better prognosis than those with ERα-negative
tumors, the number of ERα-expressing cells in tumors from 12-13-week-old PyMT
tumors were analyzed with respect to tumor grade. Consistent with patient data, ERα
expression is correlated with a lower tumor grade (p = .05) (Figure 2.5D).
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Figure 2.5 GPER expression does not affect the percent of ERα-positive cells. A)
Sections (5 µm) of tumors from 7-week-old and 12-week-old PyMT mice were stained
with an anti-ERα antibody. B) Quantification of ERα-positive cells relative to total
epithelial cells in 3 random fields in tumors from 7-week-old WT/PyMT and
KO/PyMT mice. C) Quantification of ERα-positive cells relative to total epithelial
cells in 3 random fields in tumors from 12-13-week-old WT/PyMT and KO/PyMT
mice. D) Correlation analysis between tumor grade and percent of ERα-positive cells
from 12-13-week-old mice. Differences in ERα expression were statistically analyzed
by two-tailed Student’s t-test with a p-value threshold of .05. Correlation between ERα
expression and tumor grade was analyzed using simple linear regression with a pvalue threshold of .05.
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2.4.6 GPER deficiency yields fewer metastases to the lung. While tumor size,
grade, proliferation rate, and estrogen receptor status are predictive of aggressiveness in
breast tumors, the most reliable predictor of survival in patients is the presence of distant
metastases (64, 67). The most common metastatic sites for human breast cancer are the
lungs, liver, and bone (106). PyMT tumors predominantly metastasize to the lung,
making it an appropriate model to use to evaluate metastasis (60). To assess the extent of
metastasis, the lungs of 12-13-week-old KO/PyMT and WT/PyMT mice were stained
with H&E and the number of tumor foci, designated as a group of 10 or more densely
packed cells, was determined (Figure 2.6A). Lungs from WT/PyMT mice contained 9.0 ±
1.9 metastatic foci per lung while lungs from KO/PyMT mice contained 3.8 ± 0.69
metastatic foci, demonstrating an 58% reduction in metastases in KO/PyMT mice (p <
.05) (Figure 2.6B). While the majority of mice had metastasis by this age, 83% of
KO/PyMT mice had fewer than 5 metastasis compared to 33% of WT/PyMT mice. These
data demonstrate that PyMT mice lacking GPER have a decreased incidence of
metastasis.
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Figure 2.6 Lack of GPER reduces metastatic burden in PyMT mice. A) Lungs of
WT/PyMT and KO/PyMT mice were removed when mice were 12-13-weeks-old and
stained with H&E to determine the extent of metastasis. Top image represents normal
mouse lung tissue. Bottom image represents mouse lung tissue containing tumor foci
(arrows). B) Quantification of the number of tumor foci in WT/PyMT and KO/PyMT
mice analyzed by two-tailed Student’s t-test with a p-value threshold of .05. C) The
number of mice exhibiting <5 or ≥5 metastatic foci per lung was analyzed by two-tailed
Fisher’s exact test with a p-value threshold of .05.
* p < .05
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2.5 Discussion
Several reports have demonstrated cancer cell lines proliferate in response to the
GPER-selective agonist G-1 and that E2-dependent proliferation is reduced upon
silencing of GPER (28, 41, 118, 135). While these data suggest GPER may promote
breast tumor growth, its importance in breast cancer initiation, growth and progression
remains unclear. This is the first report describing a role for GPER in an in vivo model of
breast cancer.
Initially, PyMT mice intercrossed with GPER KO mice were used to assess the
contribution of GPER to early mammary tumor development using 7-week-old mice.
Both WT/PyMT and KO/PyMT mice developed palpable tumors by 7 weeks of age,
consistent with there being no difference in tumor latency. These tumors were analyzed
for differences in proliferation and the extent of hyperplasia throughout the gland. At this
early time point, there was no difference in the proliferation rate or hyperplasia, implying
GPER does not play a role in tumor development or early tumor cell proliferation.
The role of GPER in late stage tumor growth and progression was evaluated by
measuring tumor size and distant metastasis. Tumors from KO/PyMT mice were smaller
than tumors from WT/PyMT mice, likely due to decreased tumor cell proliferation.
Further, there was a trend for KO/PyMT mice to exhibit lower grade tumors than
WT/PyMT mice, suggesting tumors from KO/PyMT mice are less aggressive than tumors
from WT/PyMT mice. While tumor size, grade and proliferation rate are used clinically
to predict patient outcomes, the best parameter to determine prognosis is the presence of
distant metastases. In breast cancer, the primary sites of metastasis are bone, liver, and
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lung. Although PyMT mice do not develop bone or liver lesions, metastatic lung foci are
routinely observed by 12 weeks of age. In this regard, there were significantly fewer
metastatic foci in the lungs of KO/PyMT mice compared to WT/PyMT mice. These data
establish a role for GPER in growth and metastasis of mammary tumors in a reliable in
vivo model of breast cancer (125). Evaluating data from early and late stages of
tumorigenesis, we propose GPER increases the aggressiveness of established tumors, but
has minimal effect on tumor development.
The classical E2 receptor ERα is known to increase proliferation rate and tumor
growth in breast tumors (6). Therefore, the tumor expression of ERα was evaluated at 7
and 12-13 weeks of age showing no difference between GPER KO and GPER WT
tumors. Staining intensity in hyperplastic regions of tumors from 7-week-old mice is faint
compared to adjacent normal tissue. Staining intensity decreases further in 12-13-weekold mice compared to hyperplasia from 7-week-old mice. Therefore, ERα may play a
dominant role in early mammary tumor development through its robust proliferative
effects, as evidenced by reduced tumor size in ovariectomized and tamoxifen treated
mice (Figure 2.1), rendering GPER KO less consequential at early times, with the
growth- and metastasis-promoting effects of GPER becoming determinant later in tumor
development as tumors lose ERα expression. While tamoxifen is an effective treatment
for ERα+ breast cancer, 30% of breast tumors do not express ERα. Further, 30% of ERα+
tumors that initially responded to tamoxifen become resistant to the ERα-targeted therapy
(136). Given the possible role of GPER in tamoxifen-resistant and ERα- tumors, GPER
could be targeted to reduce tumor growth and metastasis. Additionally, while tamoxifen
is a selective estrogen receptor modulator (SERM) that inhibits ERα in the breast, it
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activates GPER, possibly contributing to tamoxifen resistance and the development of
tamoxifen associated uterine cancer (35). Administering a GPER-selective antagonist
following or in combination with tamoxifen could represent an approach to inhibit
resistance and improve the efficacy of tamoxifen and other SERMs.
This is the first in vivo study demonstrating a role for GPER in the progression of
breast cancer, which reveals a novel target in hormone therapy for breast cancer. For
decades, tamoxifen has been successful in treating patients with breast cancer, although
many tumors are initially resistant or develop resistance, and when breast tumors recur,
many are resistant to tamoxifen (137). GPER is expressed in 60% of ERα- tumors, and
GPER expression is associated with increased recurrence after adjuvant treatment with
tamoxifen as a monotherapy (119, 121). Therefore, it is possible that targeting GPER
would increase patient survival in women with the more aggressive ERα- tumors and
could be an effective combination treatment with tamoxifen. Additionally, GPERselective small molecule inhibitors (G15 and G36) have been developed, making GPER
an attractive clinical target.
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CHAPTER 3
IDENTIFYING THE ROLE OF GPER IN THE
MICROENVIRONMENT OF MAMMARY CARCINOMA
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3.1 Abstract
Traditionally, mutations or signaling pathways that drive breast cancer are
analyzed in tumor epithelial cells; however, breast cancer growth and its ability to
metastasis is also regulated by the tumor microenvironment. The microenvironment is
comprised of fibroblasts, extracellular matrix components, immune cells, blood vessels,
and lymphatic vessels, which can each be modulated to affect tumor growth and
aggressiveness. In addition to it effects in cultured tumor cells, G protein-coupled
estrogen receptor (GPER) increases the proliferation and migration of fibroblasts, one of
the central members of the tumor microenvironment, suggesting GPER stimulation in the
tumor microenvironment could enhance tumorigenesis. Additionally, knocking out GPER
in the MMTV-PyMT model of breast carcinogenesis decreases tumor size and metastasis,
although the distinct roles of GPER in the tumor parenchyma versus the
microenvironment are unclear (Chapter 2). To distinguish the effects of GPER in the
tumor parenchyma and microenvironment, GPER expressing PyMT tumor epithelial cells
(WT/PyMT) were orthotopically transplanted into GPER WT and GPER KO recipient
mice and analyzed for tumor growth and metastasis. The reciprocal experiment
(KO/PyMT cells into WT and KO mice) was also performed. WT/PyMT tumor size was
unaffected by the microenvironment, whereas KO/PyMT tumors were larger in KO
recipient mice compared to WT recipient mice. With respect to metastasis, WT/PyMT
mice metastasized more frequently in WT compared with KO mice, while KO/PyMT cell
metastasis was unaffected by the microenvironment. These data suggest GPER
expression in the tumor microenvironment regulates tumor growth and metastasis.
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3.2 Introduction
Breast cancer is classically defined as dysregulation of epithelial cells leading to
uncontrolled proliferation, increased cell survival, and the ability to metastasize to distant
sites. Although breast cancer manifests in epithelial cells, changes in the
microenvironment are critical to formation and progression of breast tumors (138). The
mammary gland is a secretory organ formed by a branching duct structure embedded in
the mammary fat pad. The ducts are comprised of an inner layer of luminal epithelial
cells responsible for milk secretion surrounded by an outer layer of myoepithelial cells.
The luminal epithelial cells make up the parenchyma of the breast and are supported by
their microenvironment, or stroma, which includes myoepithelial cells, blood vessels,
lymphatic vessels, immune cells, fibroblasts, and extracellular matrix (ECM) (12). The
stroma communicates with the epithelium to maintain normal breast homeostasis through
many mechanisms including direct cell-cell contact, release of paracrine factors, and
changes in the structure and components of the ECM. Consequently, alterations in the
normal microenvironment lead to disruption of normal gland function and, conceivably,
cancer development (77, 82, 139). Additionally, tumor epithelial cells release signals to
modulate the microenvironment. Once the microenvironment has been modified, it
enhances tumor growth and proliferation (Figure 3.1).
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Figure 3.1 Mammary tumor microenvironment. Mammary tumors are surrounded
by a complex microenvironment that includes fibroblasts that secrete ECM, blood
vessels, lymphatic vessels, and multiple types of immune cells (2).
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Macrophages are part of the innate immune system that perform a versatile role in
the microenvironmental regulation of carcinogenesis. Tissue remodeling that occurs
during tumor formation releases pro-inflammatory cytokines, which recruit and activate
macrophages. Once activated, macrophages release tumoricidal products, such as tumor
necrosis factor-α (TNFα) and nitric oxide (140). Inflammatory macrophages are also
capable of recognizing tumor cell neo-antigens, phagocytosing tumor cells, and
presenting antigens to the adaptive immune system, thereby activating the adaptive
immune system. Tumoricidal capabilities of macrophages have been observed in vitro in
co-culture experiments as well as in vivo in bone marrow and liver metastases (89, 141).
Historically, it was believed successful tumors simply excluded macrophages to evade
their tumoricidal actions. However, it was later recognized that low-level chronic
inflammation occurring in disease states, such as ulcerative colitis, correlates with tumor
formation (142). Using mouse models of inflammatory disease, it was determined
“smoldering inflammation” enhances tumor development through production of reactive
oxygen species (ROS) causing DNA damage and mutations in epithelial cells.
Additionally, in over 80% of tumors, including thyroid, lung, hepatocelluar, and breast
carcinoma, the presence of infiltrating macrophages is correlated with poor prognosis. In
breast cancer, macrophages are recruited to benign tumors as the tumors shift to
malignancy, indicating macrophages may enhance cancer progression (89). These
clinical observations resulted in further investigation into the role of tumor-associated
macrophages (TAMs). In mouse models of carcinogenesis, depleting macrophages by
administering chlodronate-containing liposomes reduces angiogenesis, tumor growth, and
metastasis (85, 141, 143). Additionally, tumors in MMTV-PyMT mice crossed with
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Csf1op/op transgenic mice contain significantly fewer TAMs, do not progress to
malignancy as rapidly as WT mice and are unable to metastasize (126). It is now well
accepted that, although macrophages are able recognize and kill precancerous cells, they
also initiate epithelial cell transformation during chronic inflammation. , and in existing
tumors, macrophages increase tumor growth and enhance the ability of tumors to
metastasize.
Macrophages respond to multiple cues in their environment including cytokines
and steroid hormones, such as 17β-estradiol (E2). Although the consequences of E2 in
macrophages are controversial, in many circumstances, E2 decreases the inflammatory
response of macrophages (91). Premenopausal women have lower circulating levels of
TNF-α, a proinflammatory cytokine, compared with postmenopausal women and men
under normal conditions. Premenopausal women also display an attenuated TNF-α
response during septic shock as compared with men, providing in vivo evidence E2 may
affect macrophage polarization. In cultured human primary macrophages, E2 inhibits the
translocation of NF-κB, decreasing the expression of TNF-α and presumably other
proinflammatory cytokines (144). Additionally, in the autoimmune disease multiple
sclerosis (MS), E2 is anti-inflammatory and neuroprotective. Until recently, the actions of
E2 in macrophages have been largely attributed to ERα and to a lesser extent ERβ. In
2009, Blasko et al., describe a role for the novel E2 receptor G protein-coupled estrogen
receptor (GPER) in decreasing secretion of TNF-α and IL-6 from macrophages, thereby
inhibiting disease progression in the experimental allergic encephalomyelitis (EAE), a
mouse model of MS (90). Because E2 is present in high levels in the breast cancer
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microenvironment, it may decrease macrophage secretion of pro-inflammatory cytokines,
consequently inhibiting the anti-tumor immune response via ERα or GPER (101).
In chapter 2 of this dissertation, in vivo evidence is provided for GPER
augmenting late stage breast cancer growth and metastasis in the MMTV-PyMT model of
mammary tumorigenesis. In this model, lack of GPER reduces tumor cell proliferation
and metastasis; however, because a global GPER KO mouse was used, it is unclear if the
effects of GPER are due to its actions in the tumor parenchyma or microenvironment.
Therefore, we employed an orthotopic transplant model to examine the discrete effects of
GPER in the tumor cells and microenvironment (Figure 3.2). Epithelial cells from PyMT
mice expressing GPER (WT/PyMT) were orthotopically transplanted into GPER WT or
KO recipient mice to evaluate the effect of the microenvironment on tumor growth and
metastasis. No difference in tumor size was observed when WT/PyMT cells were
transplanted into either WT or KO recipient mice. Evaluation of lung metastasis revealed
WT/PyMT cells metastasize more frequently in WT recipient mice than in KO mice. The
reciprocal experiment was also performed in which epithelial cells from PyMT mice
lacking GPER (KO/PyMT) mice were orthotopically transplanted into WT and KO
recipient mice. KO/PyMT cells generated larger tumors in KO recipient mice compared
to WT recipient mice, although there was no difference in the extent of metastasis.
Because macrophages are required for metastasis in the MMTV-PyMT model and E2
affects macrophage polarization through GPER stimulation, WT/PyMT cells were
orthotopically transplanted in combination with GPER WT or KO bone marrow derived
macrophages (WT/BMM or KO/BMM, respectively) to investigate the role of
macrophages in tumor size and metastasis. Larger tumors formed in the presence of
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WT/BMM compared to KO/BMM, although the number of metastasis between mice
receiving WT/BMM or KO/BMM was not different. Therefore, it can be concluded
GPER expression in the microenvironment affects tumor growth and metastasis.
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Figure 3.2 Orthotopic transplant model. Tumors were removed from 7-week-old
PyMT mice, minced, and digested. Organoids were purified via differential
centrifugation and stored in liquid nitrogen. The number 4 mammary fat pads of WT
and KO recipient mice were cleared when mice were 3-weeks-old. When recipient
mice were 5-weeks-old, cells were orthotopically transplanted into the cleared number
4 mammary fat pads.
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3.3 Methods
3.3.1 Mice. FVB/N-Tg(MMTV-PyVT)634Mul/J (MMTV-PyMT) and FVB/NJ mice
were purchased from The Jackson Laboratory (Bar Harbor, ME). GPER KO mice were
provided by Jan Rosenbaum (Proctor & Gamble, Cincinnati, OH) and described
previously (133). GPER KO mice were backcrossed 10 generations onto FVB/NJ mice.
Animals were housed in the animal research facility at the University of New Mexico
Health Sciences Center and maintained under a controlled temperature of 22–23°C with a
12-h light, 12-h dark cycle and fed a normal chow ad libitum. All procedures were
approved by and carried out in accordance with institutional protocols.

3.3.2 Primary mammary tumor epithelial cell isolation. Tumors were removed
from 7-week-old GPER WT or KO PyMT mice. Tumors were minced in epithelial
medium containing DMEM-F12 (cellgro, mediatech) + 5% FBS (JRH Biosciences) 1%
penicillin-streptamycin-glutamine (GIBCO) + 10 µg/ml insulin (Cell Applications) +
0.5U/ml hydrocortisone (Sigma-Aldrich) + 10 ng/ml EGF (Molecular Probes). Minced
tumors were dissociated in epithelial medium containing 3 mg/ml collagenase A (Roche)
and 250 U/ml Hyaluronidase (Sigma-Aldrich) for 3 hours at 37°C with gentle rocking.
Dissociated cells were strained through a 500 µM sterile mesh nylon filter. Filtered cells
were centrifuged at 48 g for 3 min. The resulting pellet was washed three times with
HBSS + 5% FBS and centrifuged at 200 g for 2 min. The resulting organoids were
resuspended in epithelial cell media + 10% DMSO and stored in liquid nitrogen.

3.3.3 Fat pad clearing and tumor cell transplantation. When WT or KO FVB/NJ
mice were 3-weeks-old, the number 4 mammary fat pads were cleared to remove the
epithelium, while leaving part of the mammary fat pad. An inverse Y incision was made
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on the ventral side of the mouse, and the skin was gently separated from the underlying
muscle to expose each number 4 mammary gland. The mammary tissue proximal to the
fat pad lymph node was removed. Saline was instilled into the subcutaneous space to
prevent fibrotic adhesions, and the skin incision was closed using steel tissue clips (ez
CLIPS, Stoelting). Two weeks after the fat pad was cleared, the inverse Y incision was
reopened, and 10,000 WT/PyMT or KO/PyMT organoids resuspended in 30 µl of phenol
red-free DMEM-F12 were injected directly into each cleared number 4 mammary fat pad.
The skin incision was closed using steel tissue clips.

3.3.4 Isolation and differentiation of bone marrow derived macrophages
(BMM). Bone marrow from GPER WT or KO FVB/NJ mice was collected from 6-8week-old mice as previously described. Briefly, the femur and tibia were cleaned and
rinsed in 70% ethanol. The epiphyses was removed from both ends of the bone and the
marrow was flushed out with ice cold DMEM + 10% FBS using a 27 G needle. The bone
marrow was passed through a 40 µm cell strainer (BD Biosciences) and centrifuged at
100 g for 5 min to isolate bone marrow cells. The cells were resuspended in DMEM +
10% FBS + 20% L929 conditioned media (differentiation media) and seeded in a 150
mm untreated petri dish. The media was changed on days 4 and 6, and the cells were used
on day 7. To generate L929 conditioned medium, L929 cells were grown to confluency.
Once confluent, the media was changed and left for 7 days, at which time the media was
collected and filtered through a 0.22 µm polyethersulfone membrane bottle top vacuum
filter (Corning, Sigma-Aldrich).

3.3.5 Co-injection of WT/PyMT cells with WT/BMM and KO/BMM. A clonal
cell line previously generated from a PyMT mouse was used in this experiment and
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cultured in epithelial cell medium. WT/PyMT cells mixed with WT/BMM or KO/BMM
at a 1:9 or 1:3 ratio were resuspended at a concentration of 1x106 cells per 100 µl in
phenol red-free DMEM-F12. Cells were orthotopically injected into the un-cleared
number 4 mammary glands of a FVB/NJ mouse.

3.4 Results
3.4.1 GPER expression in the microenvironment of GPER+ tumors does not
affect tumor size, but increases the incidence of metastasis. E2 is known to
enhance proliferation and metastasis of tumors via activation of ERα, and we provide
evidence in chapter 2 that GPER expression contributes to E2-mediated advancement of
breast cancer. To further elucidate the role of GPER in the tumor parenchyma and
microenvironment, an orthotopic transplant model was used (Figure 3.2). WT/PyMT
cells were orthotopically injected into the cleared number 4 mammary fat pads of WT
and KO recipient mice. Tumors were removed and weighed as a measure of tumor size at
various time points after injection. Five weeks post-injection, no difference in tumor size
was observed between WT (0.32 ± 0.07 g) and KO (0.23 ± 0.03 g) recipient mice (p =
.25) (Figure 3.3A). Tumor weights appeared to deviate between WT (0.29 ± 0.08 g) and
KO (0.45 ± 0.1 g) at 8 weeks after cell injection, although there was no statistical
difference between the two groups (p = .23) (Figure 3.3B). A final time point of 12 weeks
post-injection was examined, and again, there was no difference between tumor size in
WT (3.042 ± 0.54) and KO (2.638 ± 0.74) recipient mice (p = .67), suggesting the
microenvironment does not affect the size of WT/PyMT tumors (Figure 3.3C).
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Figure 3.3 GPER expression in the microenvironment does not affect tumor size
of WT/PyMT tumors. WT/PyMT cells were orthotopically transplanted into WT and
KO recipient mice. Tumors were removed and weighed at different time points after
tumor injection including: A) 5 weeks B) 8 weeks or C) 12 weeks. Results were
analyzed by Student’s t-test.
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In addition to influencing tumor size, the microenvironment regulates the ability
of tumor cells to metastasize by modifying the ECM, increasing vascular permeability,
and increasing cell migration and invasion into the surrounding stroma (2, 82).
Previously, it was determined the lack of GPER inhibits metastasis in the MMTV-PyMT
model (chapter 2); however, it is unclear if this effect is due to the absence of GPER in
the tumor parenchyma or microenvironment. Accordingly, the lungs from WT and KO
mice with WT/PyMT tumors were sectioned, stained with H&E, and analyzed for the
presence of distant metastases (Figure 3.4A). No metastatic foci were observed in the
lungs of KO mice, whereas lungs from 63% of the lungs from mice contained metastases
(p=.03) (Figure 3.5B). These data demonstrate GPER expression in the tumor
microenvironment augments metastasis of WT/PyMT tumors, while not affecting tumor
size.
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Figure 3.4 WT/PyMT cells metastasize more frequently in WT mice
compared with KO mice. Lungs of WT and KO mice bearing WT/PyMT tumors
were analyzed for the presence of metastatic foci. Data are displayed as the
percentage of mice with metastases. Statistical analysis was performed using
Fisher’s exact test.
* p < .05
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3.4.2 GPER- tumors are larger in a microenvironment lacking GPER, but the
extent of metastasis in unaffected by microenvironmental GPER expression.
Although clinically the majority (62%) of invasive breast tumors express GPER in the
tumor epithelium, a large proportion of breast tumors do not (119). Therefore, to
determine how GPER expression in the microenvironment of a GPER- tumor affects
tumor growth and progression, KO/PyMT cells were orthotopically transplanted into WT
and KO recipient mice. Tumors were resected at 12 weeks after transplantation and
weighed to determine tumor size. Tumors in KO recipient mice were 2-fold larger than
those in WT recipient mice (p = .003) (Figure 3.5), demonstrating a growth advantage for
KO/PyMT tumors in a GPER- microenvironment.
The lungs of WT and KO mice bearing tumors from KO/PyMT cells were
assessed in the same manner described above. No difference was observed between the
percent of mice displaying metastasis between WT (31%) and KO (45%) mice (p = .50)
(Figure 3.6A). While the incidence of metastasis was not different, it is possible the
metastatic burden, defined as the number of metastases per lung, could be different
between WT and KO mice. Therefore, the number of metastatic foci in each lung was
assessed. WT mice had 2.7 ± 1.4 metastatic foci per lung compared to 1.9 ± 1.0 foci in
KO mice (p = .70) (Figure 3.6B). These data suggest that although the absence of GPER
in the microenvironment results in larger KO/PyMT tumors, the microenvironmental
expression of GPER does not affect the ability of GPER- tumors to metastasize.
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Figure 3.5 KO/PyMT tumors are larger in a KO vs. WT microenvironment A)
KO/PyMT cells were orthotopically transplanted into WT and KO recipient mice.
Tumors were removed and weighed 12 weeks after transplantation. Results were
analyzed by Student’s t-test.
** p < .01
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Figure 3.6 GPER expression in the microenvironment of KO/PyMT tumors
does not affect metastasis. A) Lungs from WT and KO mice bearing KO/PyMT
tumors were analyzed for the presence of metastases. Statistical analysis was
performed using Fisher’s exact test. B) The number of metastatic foci/lung was
determined. Statistical analysis was done with Student’s t-test with a p-value
threshold of .05.
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3.4.3 Lacking GPER in TAMs decreases tumor size. Altering microenvironmental
GPER expression influenced tumor size and incidence of metastasis; however, the cell
types responsible for these differences remain unknown. TAMs enhance tumor growth
and metastasis by releasing growth factors, such as EGF, and by dampening the antitumor immune response (89). To examine the effect of GPER expression in
macrophages on tumor size, a mixture of 90% WT/PyMT cells and 10% WT/BMM or
KO/BMM was orthotopically transplanted into WT mice (Figure 3.7). Tumors coinjected with KO/BMM demonstrated a 30% reduction in tumor size (0.37 ± 0.03 g)
compared to tumors with WT/BMM (0.5 ± 0.05 g) (p < .05) (Figure 3.8A). To determine
if the effects of altering GPER expression in macrophages could be enhanced, the
macrophage population was increased to 25% of the transplanted cells. In agreement with
data obtained from 10% macrophages, there was a trend for tumors to be 20% smaller
when co-injected with KO/BMM (5.1 ± 0.34) compared with WT/BMM (4.2 ± 0.15) (p =
.08) (Figure 3.8B). These data demonstrate that lacking GPER expression in TAMs
decreases tumor growth, suggesting GPER stimulation in macrophages enhances
mammary tumor growth.
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Figure 3.7 Orthotopic transplant of macrophages and WT/PyMT cells. WT/PyMT
cells were mixed with WT/BMM or KO/BMM in culture and orthotopically
transplanted into a WT mouse. The ratio of BMM:PyMT cells varied between 1:9 and
1:3.
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Figure 3.8 Tumors containing KO/BMM are smaller than tumors containing
WT/BMM. WT/PyMT cells co-injected with 10% (A) or 25% (B) WT/BMM or
KO/BMM were weighed as a measure of tumor size. Results were analyzed using
Student’s t-test.
* p < .05
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3.4.4 GPER expression in macrophages does not affect extent of metastasis.
Previously published data demonstrate TAMs are necessary for tumors to metastasize in
the PyMT model (126). Further, in breast cancer models, a CSF-1-EGF feedback loop
has been described, in which the tumor cells release CSF-1 to recruit macrophages
causing the macrophages to release EGF initiating epithelial cell migration toward the
vasculature (145). This feedback loop enhances breast cancer metastasis. To examine the
role of GPER expression in macrophages on metastasis, the lungs of mice co-injected
with WT/PyMT cells and either WT/BMM or KO/BMM were stained with H&E and
analyzed for the presence of metastasis. No significant difference was observed in the
percent of mice with metastases from tumors containing WT/BMM (50%) or KO/BMM
(33%) (Figure 3.9A). There was also no difference in metastatic burden, defined as the
number of metastases per lung, between tumors with WT/BMM (0.83 ± 0.48) or
KO/BMM (0.50 ± 0.34) (Figure 3.9B). Therefore, GPER expression in macrophages does
not affect the ability of tumors to metastasize.
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Figure 3.9 The co-injection of WT/BMM or KO/BMM with PyMT cells does not
affect the extent of metastasis. A) The lungs of mice co-injected with PyMT cells
and WT/BMM or KO/BMM were analyzed for the presence of distant metastases.
Results were statistically analyzed using Fisher’s exact test. B) The number of
metastases per lung were counted. Results were analyzed using Student’s t-test.
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3.5 Discussion
Although it has been demonstrated that GPER plays a role in breast cancer
progression, its precise role in tumor growth and metastasis remains to be clarified.
Previously, we established that lack of GPER in the PyMT model of mammary
carcinogenesis decreases tumor size and extent of metastasis. Because the GPER KO
PyMT mice were generated using a global KO mouse, it was not possible to determine if
the observed differences in tumor progression were due to absence of GPER in the tumor
parenchyma or microenvironment. Accordingly, WT/PyMT and KO/PyMT cells were
each orthotopically transplanted into WT and KO recipient mice. The size of WT/PyMT
tumors was not different regardless of GPER expression in the microenvironment. These
data suggest proliferation and survival effects of GPER expression in the epithelium are
dominant to the effects of GPER in the microenvironment. In contrast, KO/PyMT tumors
were larger in KO mice than in WT mice. There are two general explanations for these
data. One is the presence of GPER in the microenvironment inhibits tumor growth.
Therefore, when GPER is absent in the microenvironment, tumor cells are released from
negative regulation by microenvironmental GPER and grow more rapidly. Another
explanation is that lacking GPER in the microenvironment directly stimulates tumor
growth. Resolving the mechanism of microenvironmental GPER regulation of tumor
growth is not trivial, and requires analysis of individual components in the
microenvironment. Additionally, because tumor cells are transplanted into a global KO
mouse, it is important to investigate the effects of GPER expression on the
macroenvironment, including release of hormones such as insulin, estrogen,
progesterone, and glucocorticoids, which could affect tumor size.
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Just as the microenvironment is involved in tumor growth, it also regulates
metastasis. Therefore, lungs of WT and KO recipient mice bearing WT/PyMT tumors
were analyzed for the presence of metastatic foci. WT/PyMT cells metastasized
frequently in WT mice, although they did not metastasize in KO mice, demonstrating the
WT microenvironment positively regulates the ability of GPER+ tumor cells to
metastasize. The observed difference in metastasis may be due to changes in the
microenvironment of the primary tumor, the microenvironment of the metastatic site,
changes in vasculature, or global changes that modulate cell survival as they metastasize.
Conversely, no differences in metastasis were observed when KO/PyMT cells were
transplanted into WT or KO mice, which may be due to an indirect effect of tumor size.
Among other variables, increased tumor size is a risk factor for metastasis (146).
Consequently, because KO/PyMT tumors are larger in KO mice they may metastasize
more frequently than smaller tumors in WT mice, masking the positive effects of
microenvironmental GPER on metastasis. Therefore, lungs of KO and WT mice should
be analyzed for metastatic foci when KO/PyMT tumors are the same size rather than
being analyzed at the same time point.
Multiple components of the microenvironment are involved in regulating
mammary tumor growth and metastasis (2, 82). In mouse models of mammary
carcinogenesis, macrophages enhance tumor progression through the secretion of growth
factors and anti-inflammatory cytokines after being polarized by soluble factors from
tumor microenvironment (89). GPER decreases the LPS-induced secretion of
inflammatory cytokines, but in the context of a mammary tumor, the effects of GPER on
macrophage polarization are unknown (90). To determine if GPER expression in
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macrophages affects tumor growth and metastasis, WT/BMM and KO/BMM were
orthotopically co-injected with WT/PyMT cells into a WT recipient mouse. Co-injection
of WT/PyMT cells and WT/BMM resulted in larger tumors than when KO/BMM were
co-injected; however, there was no affect on the ability of the tumors to metastasize.
These data suggest that in the context of mammary carcinoma, GPER expression in
TAMs may augment tumor growth. There are many possibilities for why the absence of
GPER expression in macrophages does not affect metastasis in this model. One
possibility is GPER expression in macrophages may increase the secretion of antiinflammatory cytokines, dampening the immune response to the tumor, resulting in
increased tumor cell survival. Additionally, the expression of GPER in macrophages may
increase the release of growth factors, thereby augmenting tumor growth. However,
increasing tumor growth and survival does not necessarily correlate with metastatic
capability (147). Furthermore, intrinsic experimental complications exist. In the
experiment, tumor cells and BMM are transplanted into GPER WT immunocompetent
mice. Consequently, the transplanted tumors recruit endogenous GPER WT macrophages
to the tumor site, diluting the possible effects of the injected KO/BMM. Additionally, the
number of injected BMM retained at the tumor site is unknown. Therefore, although 1025% of the injected cells were KO/BMM, many of these macrophages may have
migrated away from the tumor. The experimental design would be improved by using a
conditional macrophage depletion model, such as the MAFI mouse, as the recipient mice,
thereby inhibiting endogenous macrophages recruitment to the tumor site (148). Further,
co-injecting labeled macrophages would help estimate the number of macrophages
retained by the primary tumor. These experimental changes would ensure the effects
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mediated by GPER KO macrophages would not be obscured by endogenously recruited
macrophages, and the number of macrophages could be optimized for possible migration
away from the tumor.
Collectively, these data demonstrate a role for GPER expression in the tumor
microenvironment on both tumor growth and progression, although the effects seem to be
contradictory in some instances. For example, although the absence of GPER in the
microenvironment does not affect tumor size in WT/PyMT derived tumors, selectively
lacking GPER in macrophages decreases tumor size formed by WT/PyMT cells. This
suggests the role of GPER in the tumor microenvironment is multifaceted, and while
GPER expression in TAMs enhances tumor growth, GPER expression in another
component of the microenvironment may inhibit tumor growth. Consequently, a more
thorough analysis of the activity of GPER in individual components of the
microenvironment would help in the development of GPER-targeted therapies for breast
cancer.
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CHAPTER 4
IN VIVO ADMINISTRATION OF GPER-SELECTIVE
ANTAGONIST G36 REDUCES MAMMARY TUMOR METASTASIS

93

4.1 Abstract
Treatment for breast cancer is shifting away from chemotherapy and toward
therapeutics aimed at targeting specific proteins or mutations present in an individual
patient’s tumor. One successful target is the classical estrogen receptor, ERα, which is
inhibited in breast cancer by tamoxifen thereby decreasing breast cancer-related
mortality. Tamoxifen and other targeted drugs not only improve patient outcomes, but
also decrease toxicity associated with traditional chemotherapeutics. Unfortunately, there
are limited clinically available targeted therapies for breast cancer, and resistance to
therapy is a recurring obstacle. To enhance the successful use of tailored treatment in
patients with breast cancer, novel therapeutic targets need to be discovered. The G
protein coupled estrogen receptor (GPER) has been implicated in breast cancer
progression both in vitro and in vivo. However, the effect of GPER-selective compounds
on breast cancer growth and metastasis remains unknown. Using the PyMT mouse model
of tumorigenesis we demonstrate that pharmacologically inhibiting GPER decreases E2mediated lung metastasis, although it has no effect on tumor size or grade. Therefore,
GPER may be a novel therapeutic target to decrease metastasis.

4.2 Introduction
Breast cancer accounts for 30% of new cancer cases among women and
approximately 40,000 women die of breast cancer in the United States each year (63).
Because of early detection and advances in treatment, breast cancer associated mortality
has significantly decreased. One major advance in breast cancer treatment was
recognition that the classical estrogen receptor, ERα, drives proliferation of breast cancer
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cells (6). A higher proliferation rate leads to an increased mutation rate, more advanced
tumor grade, and increased frequency of metastasis (94). Therefore, drugs designed to
inhibit ERα or the release of estrogen are now the standard of care for patients with ERα
expressing tumors (111). Additionally, it was determined that 25% of breast tumors
overexpress the epidermal growth factor family member ErbB2/HER2/neu, which is also
implicated in driving tumor progression. This discovery led to the development of the
small molecule inhibitor lapatinib and anti-HER2 monoclonal antibody trastuzumab.
ERα and HER2 targeted therapies are extremely successful due to inhibition of receptors
known to drive the progression of breast cancer (69). Furthermore, they are selectively
used in patient populations whose tumors express ERα or overexpress HER2, increasing
their efficacy and decreasing side effects in patients who would not benefit from
treatment (149). Unfortunately, many tumors eventually become resistant to targeted
therapies. The intrinsic heterogeneity of tumors is a common cause of drug resistance.
For example, a breast tumor is classified as ERα+ if 1% or more of its cells express the
receptor. However, subsequent to ERα inhibition, ERα- cells evolve to drive tumor
growth and progression (150, 151). Therefore, there is an impetus to discover novel
targeted therapies to combat resistance. There are multiple means to detect novel tumor
drivers including high-throughput screening, cancer genome searches to identify
mutations or duplication, and hypothesis driven research on individual proteins (152).
Using hypothesis driven research, the non-classical estrogen receptor, G protein-coupled
estrogen receptor 1 (GPER) has been implicated in the progression of breast cancer and
as a possible therapeutic target.
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GPER was initially found to mediate rapid E2-dependent signaling in MCF7
(ERα+, GPER+) and SKBR3 (ERα-, GPER+) cells via transactivation of EGFR causing
the activation of MAPK and PI3K, known tumor promoters (35, 37). Further, activation
of GPER in vitro stimulates proliferation and migration of breast cancer cells that are
inhibited by silencing GPER expression (41, 118). Although GPER appears to enhance
tumorigenic features of breast cancer cells in vitro, its clinical value was questioned.
Therefore, multiple groups analyzed GPER expression in patient samples with respect to
clinical parameters of poor prognosis and found GPER expression in primary tumors
correlated with increased tumor size, distant metastasis, and increased recurrence (119,
121, 131). While these data strongly implicate GPER in the progression of breast cancer,
direct in vivo evidence was still lacking. Accordingly, we used the MMTV-PyMT
(PyMT) model of mouse mammary carcinogenesis. PyMT mice were intercrossed with
GPER knockout mice to analyze tumor progression with respect to GPER expression. We
demonstrated mice lacking GPER have smaller tumors, decreased tumor grade, and
reduced number of metastases compared with WT PyMT mice (chapter 2). These in vivo
data demonstrate that the lack of GPER hinders mammary tumor progression, suggesting
GPER enhances tumorigenesis. Therefore, in vitro, in vivo, and clinical data collectively
indicate GPER enhances tumor growth and metastasis.
One of the most widely used adjuvant therapies in breast cancer is the selective
estrogen receptor modulator (SERM) tamoxifen, which inhibits ERα in breast tissue. It is
estimated 30% of breast tumors are initially resistant to tamoxifen because they lack
ERα, and 50% of ERα expressing tumors develop resistance (136). There are many
explanations for tamoxifen resistance including non-classical activation of ERα via the
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MAPK cascade, increased E2 sensitivity in the tumor cells, or E2-independent growth
through manipulation of another signaling pathway such as HER2 (103). However, a
new hypothesis for tamoxifen resistance was made upon discovery of GPER. It was
suggested that while tamoxifen inhibits ERα-mediated E2 signaling, GPER-mediated
signaling is still intact, leading to decreased efficacy of tamoxifen. Furthermore,
tamoxifen is a GPER agonist that augments cell proliferation via transactivation of
EGFR. Therefore, not only is GPER-mediated E2 signaling not inhibited by tamoxifen,
but tamoxifen also activates GPER-dependent cell proliferation (120). In patient samples
analyzed for GPER expression, it was discovered that 40% of ERα+ tumors express
GPER (119). Further, GPER expression correlated with increased recurrence after
adjuvant monotherapy with tamoxifen. Thus, it is possible that inhibiting GPER while
administering tamoxifen would reduce resistance and recurrence. While some patients
develop resistance to tamoxifen, other patients do not express ERα and thus, cannot be
treated with tamoxifen. 50% of ERα- tumors express GPER, suggesting there may be an
intact, E2-dependent pathway driving proliferation and GPER could be a therapeutic
target in ERα- tumors (119). Therefore, pharmacologically inhibiting GPER in breast
cancer could decrease tamoxifen resistance as well as treat patients whose tumors do not
express ERα.
A GPER-selective agonist (G-1) and antagonist (G36) were developed using
computer modeling, flow cytometric binding assays, and synthetic chemistry (44, 46). G1 stimulates cell proliferation and migration in a GPER-dependent manner in cultured
breast cancer cells through transactivation of EGFR, resulting in MAPK and PI3K
activation (44). Therefore, G-1 stimulation of GPER activates similar, if not identical,
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pathways as the endogenous ligand E2, and has been widely used in vitro and in vivo to
dissect the physiologic roles of GPER (44, 90, 135). Conversely, G36 has been
demonstrated to inhibit GPER-dependent Ca++ mobilization, PI3K activation, and MAPK
activation following E2 or G-1 stimulation. Neither of these compounds demonstrates
binding to ERα or ERβ or activation of transcription downstream of the estrogen
response element (ERE), validating their selectivity for GPER at concentrations up to 10
µM (46). These compounds can be successfully used in vivo, in the presence of all three
estrogen receptors to isolate the effects of GPER and determine the outcome of GPERtargeted therapy. Therefore, to delineate the consequences of GPER-targeted therapy in
breast cancer, MMTV-PyMT mice were ovariectomized and treated with 90-day release
pellets containing no compound (sham), G-1, E2, G36, and E2 in combination with G36
(E2+G36) (Figure 4.1). While tumor size increased compared to sham with the addition
of E2, G-1 had no effect, and G36 was unable to inhibit the E2-mediated tumor growth.
The extent of metastasis was increased with the addition of E2 but was unaffected by G-1
when compared with sham pellet. However, G36 reduced E2-mediated metastasis, and
mice receiving G36 in the absence of E2 exhibited no metastases. These data suggest that
although targeting GPER does not affect tumor size, inhibiting GPER reduces the ability
of the tumor to metastasize, making GPER a potential therapeutic target in patients with
breast cancer.
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Figure 4.1 Experimental protocol for treatment with GPER-selective
compounds. PyMT mice were ovariectomized when mice were 3-weeks-old to
remove the majority of circulating estrogen. When mice were 4-weeks-old, 90-day
release pellets were subcutaneously implanted on the dorsal side of the mice. Pellets
contained E2 (0.36 mg/pellet), G-1 (3 mg/pellet), G36 (2mg/pellet), and E2 + G36, in
which an E2 and a G36 pellet were both implanted. Tumors were resected when
mice were 12-weeks-old and weighed as a measurement of tumor size. Lungs were
also removed to determine extent of metastasis.
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4.3 Methods
4.3.1 Mice. FVB/N-Tg(MMTV-PyVT)643Mul/J (MMTV-PyMT) mice were purchased
from The Jackson Laboratory (Bar Harbor, ME). Animals were housed in the animal
research facility at the University of New Mexico. They were maintained on a 12-h light
and 12-h dark cycle with a controlled temperature of 22-23°C and fed normal chow ad
libitum. Mice were ovariectomized at 3 weeks of age to decrease endogenous E2
production as described previously (chapter 2). At 4 weeks of age, 90-day release pellets
were subcutaneously implanted on the dorsal midsection of the mouse. Pellets were
purchased from Innovative Research of America and contained E2 (0.36 mg/pellet), G-1
(3 mg/pellet), and G36 (2 mg/pellet). Mice in the E2+G36 group has 2 pellets implanted,
one with each compound. Tumors and lungs were resected when mice were 12 weeks of
age. Tumors and the left lung were fixed in 4% PFA at room temperature overnight and
embedded in paraffin. The right lung was stored in Trizol (Sigma-Aldrich) at -80OC to
preserve RNA. All procedures were approved by and carried out in accordance with the
institutional protocols.

4.3.2 Histologic analysis of tumor sections. Three 5 µm sections of the largest tumor
from each mouse were stained with H&E. The sections were analyzed for tumor grade,
mitotic index, and extent of necrosis by veterinary pathologist Donna Kusewitt, DVM,
PhD (The University of Texas MD Anderson Cancer Center). Grading PyMT tumors was
performed as previously described (125). Briefly, grade is based on tissue architecture,
degree of cytologic atypia, and invasion into the surrounding stroma. The grades are as
follows: (1) Hyperplasia: Densely packed acini filled or bridged by epithelial cells that
have little to no cytologic atypia. There is no invasion into the surrounding stroma. (2)
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Adenoma/mammary intraepithelial neoplasia (MIN): Increased proliferation of epithelial
cells with acini mostly filled with cells. There is minimal cellular atypia and no invasion
is present. (3) Early carcinoma: Florid proliferation with loss of acinar definition. There
is moderate cellular atypia and early stromal invasion. (4) Late carcinoma: Solid sheets of
cells containing very few or no acini with a high degree of proliferation (Figure 4.2).
Marked cellular atypia and pronounced stromal invasion are present. Mitotic Index is a
measure of the proliferation rate and is defined as the number of mitotic figures per highpowered field. Lastly, necrosis is categorized as the number and size of necrotic areas.
The score of necrosis is as follows: 1 = few small areas; 2 = few larger areas or moderate
number of smaller areas; 3 = extensive areas.

4.3.3 Analysis of Lung Metastasis. Because PyMT RNA is not expressed in the lung
unless tumor cells are present as a result of metastasis, the right lung of each mouse was
analyzed for the presence of PyMT RNA by relative-quantitative PCR (qPCR). RNA was
extracted using Trizol-chloroform (Sigma-Aldrich), following the manufacturer’s
instructions. cDNA was created via reverse transcription of 1 µg RNA with the iScript
cDNA synthesis kit (BioRad) using the GeneAmp PCR system 9700 (Applied
Biosystems, Inc.) according to manufacturers directions. Quantification of PyMT mRNA
relative to 36B4 mRNA was performed using Fast SYBR Green (Molecular Probes) with
the 7500 Fast Real-Time PCR System (Applied Biosystems, Inc), using relative standard
curves, as previously described (chapter 2) Briefly, a standard curve using a mixture of
sample cDNA was created for each primer set. The Ct values each lung sample were
compared first to the standard curve to determine the relative amount of PyMT or 36B4
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cDNA in each sample. The relative amount of PyMT cDNA was then normalized to the
relative amount of 36B4 cDNA.
Three 5 µm sections separated by at least 100 µm were created from the left lung
of each mouse. The sections were stained with H&E and analyzed for the number of
metastatic foci. A metastatic focus was defined as a group of 10 or more cells stained
darkly with hematoxylin, excluding eosin positive stroma.

4.3.4 Statistical Analysis. Caliper measurements of tumors were analyzed by two-way
ANOVA with Bonferroni’s correction for multiple comparisons as a post-hoc test. Tumor
size, mitotic index, qPCR evaluation of lung metastasis, and number of lung metastases
were compared using one-way ANOVA with Bonferroni’s correction for multiple
comparison test as a post-hoc test, when applicable. Tumor grade, amount of necrosis,
and presence of metastases were compared using chi-squared analysis followed by
Fisher’s exact test with corrected p-value when applicable.
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Figure 4.2 Representative images of each tumor grade. Tumor sections (5 µm)
were stained with H&E. Tumors progress from well differentiated (grade 1) to poorly
differentiated (grade 2) as illustrated above.
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4.4 Results
4.4.1 GPER-selective compounds do not affect tumor size. We previously
determined knocking out GPER in the MMTV-PyMT model of mammary carcinogenesis
reduces tumor size and metastasis (chapter 2). While these data demonstrate decreasing
the expression of GPER in patients with breast cancer may improve patient outcome, they
do not necessarily predict the outcome of pharmacologic inhibition of GPER. Examining
the effects of GPER-selective compounds on in vivo cancer progression will aid in
determining if GPER is a good candidate for targeted therapy in breast cancer. Therefore,
PYMT mice were ovariectomized at 3 weeks of age to reduce the endogenous E2. Pellets
containing GPER-targeted compounds, including G-1, E2, E2+G36, and G36, were
subcutaneously implanted one week after ovariectomy. Mice were palpated two times per
week to determine if GPER-selective compounds affected tumor latency. All mice
displayed palpable tumors between 7 and 8 weeks of age, suggesting tumor latency is not
affected by targeting the classical estrogen receptors or GPER. Once large enough,
tumors were measured with calipers two times per week to monitor tumor growth.
Differences in tumor size between groups were first observed at 9 weeks of age.
However, no significant differences were detected until 11 weeks of age, at which time
tumors in mice treated with E2 or E2+G36 were 2-fold larger than sham treated mice.
However, G-1 and G36 alone had no effect of tumor size compared to sham (Figure
4.3A). Tumors were removed when mice were 12 weeks of age, and, similar to caliper
measurements, the average weight of tumors from mice treated with E2 (0.59 ± 0.11 g)
was about 2.5-fold greater than sham (0.22 ± 0.04 g), and G36 had no effect on E2mediated tumor growth. Further, tumors from mice treated with G-1 or G36 were not
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different in size from sham (Figure 4.3B). Collectively, these data suggest targeting
GPER with a selective agonist or antagonist does not affect the size of mammary tumors.
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Figure 4.3 The GPER-selective agonist or antagonist has no effect on tumor
size. A) PyMT mice were ovariectomized at 3 weeks of age and treatment pellets
were implanted at 4 weeks of age. Tumor measurements were obtained using
calipers beginning at 7 weeks of age through 11 weeks of age. Data was
statistically analyzed by two-way ANOVA with Bonferroni correction for multiple
comparisons as a post-hoc test. B) Tumors were resected when mice were 12weeks-old and weighed as a measurement of tumor size. One-way ANOVA with
Bonferroni correction for multiple comparisons as a post-hoc was used to
statistically analyze tumor weights.
* p < .05, compared to sham
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4.4.2 Treatment of PyMT mice with GPER-selective compounds does not
affect tumor grade, proliferation rate, or extent of necrosis. Although GPERselective compounds did not alter tumor size, it is possible parameters indicative of tumor
aggressiveness were affected. Therefore, sections from the largest tumor from each
mouse were stained with H&E and analyzed for tumor grade, mitotic index, and extent of
necrosis as markers of aggressive disease. Tumors from all treatment groups appeared as
sheets of cells with a loss of acininar definition, and where acini could be visualized, they
were completely filled with cells (Figure 4.4A). Cytologic atypia and marked areas of
necrosis were also apparent, and many tumors exhibited early stage invasion into the
surrounding stroma. Based on these histological observations, each tumor was graded.
Sham, E2 and E2+G36 all had an average tumor grade of 3 ± 0. Mice treated with G-1
had an average grade of 2.9 ± 0.1 and G36 treated mice had an average of 2.77 ± 0.15,
and were not statistically different than sham treated mice (Figure 4.4B). These data
demonstrate there is no difference in tumor grade between groups. Next, the number of
mitotic figures per high power field was determined as a measure of the proliferation rate,
which is an independent marker of poor prognosis. In all treatment groups, the mitotic
index was between 2 and 3 with no significant differences as measured by one-way
ANOVA [F(4, 38) = .26, p = .90] (Figure 4.4C). Finally, the extent of necrosis was
assessed because it is correlated with poor prognosis and aids in metastasis by promoting
cell detachment (134). There was a trend for tumors from sham and E2 treated mice to
contain increased necrosis compared with G-1, E2+G36 or G36 alone (p = .06) (Figure
4.4D). These data suggest GPER ligands do not affect parameters of poor prognosis
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typically analyzed in the primary tumor including tumor grade, cell proliferation, and
necrosis.
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Figure 4.4 GPER-selective compounds do not affect histological parameters of
poor prognosis in PyMT mice. A) Representative image of 5µm tumor sections
stained with H&E. B) Tumor sections stained with H&E were analyzed for tumor
grade. Statistical analysis was perfomed by chi-squared analysis. C) Mitotic index,
defined as the number of mitotic figures per high-powered field was determine in
sections stained with H&E. One-way ANOVA was performed to analyze results. D)
Extent of necrosis was determined by the number and size of necrotic areas present in
tumor sections stained with H&E and analyzed by chi-squared analysis.
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4.4.3 Pharmacologic inhibition of GPER impedes mammary tumor
metastasis. Tumor size, grade, and proliferation rate are used clinically to predict the
presence of metastasis and patient outcome (64). However, because metastasis is a
complex process occurring in multiple organs, it is possible to affect the frequency of
metastasis without affecting the aforementioned aspects of the primary tumor (106).
Accordingly, RNA was extracted from the right lung of each mouse to assess the
presence of PyMT RNA, which would not be present in lungs unless PyMT expressing
mammary tumor cells had metastasized. The lungs of sham, G-1, and G36 treated mice
expressed very low levels of PyMT RNA, suggesting minimal metastases. However,
there was a trend for G36 to inhibit the E2-mediated increase in PyMT RNA (Figure
4.5A). To further assess the extent of metastasis, the left lung of each mouse was paraffin
embedded, sectioned, and stained with H&E (Figure 4.5B), and the presence of
metastatic tumor foci was assessed. Although not statistically significant, it is important
to note that 33% of sham treated mice had metastatic foci as compared to 75% of E2
treated mice. Additionally, there was a trend for G36 treatment in combination with E2 to
reduce the incidence of E2-dependent metastasis by 60%. Lastly, lungs from mice treated
with G36 displayed no metastases, but again this was not significant compared to sham
(Figure 4.5C). To further assess the extent of metastasis, the number of metastases was
determined. The number of metastases was not different between sham (1.3 ± 0.8) and G1 (0.3 ± 0.2) treated mice and although G36 treated mice had no metastases, it was not
significant compared with sham. E2 treated mice had an average of 5.6 ± 2.7 metastases
per lung, which is 4 times the number of metastases compared to sham treated mice. G36
reduced the number of E2-mediated metastases to 0.77 ± 0.55, bringing metastasis in
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mice treated with E2+G36 back to the level of sham treated mice (Figure 4.5D).
Therefore, although GPER-selective compounds do not affect the size or grade of
mammary tumors, pharmacological inhibition of GPER decreases the extent of
metastasis.
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Figure 4.5 Administration of GPER-selective antagonist, G36, inhibits metastasis in
PyMT mice. A) PyMT mRNA expression in lungs from PyMT mice was analyzed by relative
quantitative PCR to determine extent of lung metastasis. Statistical analysis was performed
using one-way ANOVA. B) Representative image of a metastatic focus in lung tissue. C) The
incidence of metastasis was determined by the number of mice in each treatment group
displaying metastases in their lungs. Chi-squared test was used for statistical analysis. D) The
number of metastases in the lung of each mouse was determined to assess the extent of
metastasis. One-way ANOVA with Bonferroni correction for multiple comparisons as a posthoc was used for statistical analysis.
* p < .05, compared to sham
# p < .05, compared to E2
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4.5 Discussion
Breast cancer treatment is evolving towards tailored therapeutics for each patient,
depending on the expression profile of her tumor. This shift toward personalized
medicine has increased 5-year survival rates and decreased treatment side effects.
Unfortunately, only a handful of targeted therapies exist, and many patients are not
eligible for, or become resistant to these therapies, indicating the need to develop novel
treatment modalities (149). One obstacle in developing novel therapies is discovering
proteins or mutations that not only drive progression of breast cancer but can also be
targeted in a therapeutically meaningful manner (152). Using hypothesis driven research,
we have identified GPER as a possible therapeutic target. When absent, GPER hinders
tumor growth, decreases tumor grade, and impedes metastasis (chapter 2). However, in
chapter 3 we demonstrated that lack of GPER in the microenvironment enhances tumor
growth of GPER- cells. These seemingly contradictory results suggest that global
inhibition of GPER might not provide straightforward results. Therefore, the effects of a
GPER-selective agonist and antagonist were analyzed in the PyMT mouse model of
mammary tumorigenesis.
Ovariectomized, PyMT mice were treated with the GPER-selective agonist, G-1,
and GPER-selective antagonist, G36, in the presence and absence of E2, the endogenous
GPER ligand. Based on previously published data demonstrating G-1 increases
proliferation and migration in cultured cells and our own data that lacking GPER inhibits
tumor progression, we hypothesized G-1 would increase tumor size and metastasis (135).
However, treatment of PyMT mice with G-1 had no apparent affect on tumor size,
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proliferation rate, tumor grade, or incidence of metastasis. The apparent disagreement
between previously obtained data and the effect of G-1 in PyMT mice may point to a role
for opposing effects of GPER in the tumor microenvironment and parenchyma. For
example, targeting GPER in the stroma may inhibit tumor growth and metastasis, thereby
negating the positive effect GPER has on proliferation and metastasis when stimulated in
the tumor epithelial cells. Another possibility is that using pellets as the drug delivery
system may have affected the intratumoral concentration of G-1 over time. Analysis of
E2 release from pellets revealed a large bolus of E2 is released in the first few days after
implantation and then levels off to a much lower level (153). The dynamics of G-1
release from the pellet are unknown. However, if a large amount of G-1 is released in the
first few days after implantation, the concentration of compound subsequently released
may not be high enough to affect tumor growth and metastasis. Therefore, an in-depth
study of G-1 release from pellets needs to be performed in addition to analyzing the
effects of G-1 on the tumor microenvironment.
As expected, E2 increased tumor size. However, G36 did not reverse the E2dependent increase in tumor size, suggesting dominance of the growth-promoting effects
of ERα. Somewhat surprisingly, E2 had no effect on tumor grade or proliferation rate. A
more specific marker of proliferation such as Ki67 or phospho-histone H3 should be
analyzed as the mitotic index is a rough estimation of proliferation rate. Furthermore, a
low dose of E2 was used that may have decreased it effectiveness, especially when the
dynamics of E2 release from pellets is considered (153). However, this low-dose E2
significantly increased the incidence of metastasis, which was blocked by combination
therapy with G36, suggesting GPER stimulation is required for E2-dependent metastasis
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in the PyMT model of mammary tumorigenesis. Additionally, no metastases were
observed in mice treated with G36 alone, although this was not statistically different from
sham. Although inhibiting GPER did not affect tumor size, it did significantly decrease
extent of metastasis. Since most breast cancer mortality does not result from the primary
tumor, but rather, from metastasis to distant sites, GPER is a viable therapeutic target.
Targeting E2-mediated pathways is not a novel therapeutic strategy as tamoxifen
is the most widely used targeted therapy in breast cancer (116). Premenopausal women
with breast cancer are post-surgically treated with tamoxifen for 5 years, and
postmenopausal women are treated with a combination of aromatase inhibitors and
tamoxifen (111). However, 50% of breast tumors develop resistance to tamoxifen (136).
One possible reason for resistance is activation of GPER during tamoxifen treatment.
Therefore, inhibiting GPER in combination with tamoxifen may improve efficacy and
inhibit resistance. Further, tumors that do not express ERα may respond to G36,
providing a new option in treatment for women with ERα- tumors. Therefore,
pharmacologically inhibiting GPER in combination with current therapies is an intriguing
treatment modality to inhibit E2-mediated metastasis in breast cancer that could increase
disease free survival.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS
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5.1 Summary and Future Directions
We aimed to determine the effects of the non-classical estrogen receptor, GPER,
on breast cancer development, growth and progression. Often, E2 drives breast
carcinogenesis, and these E2-dependent effects have historically been attributed to the
classical E2 receptor, ERα, due to its ability to modulate gene transcription and increase
tumor cell proliferation and survival (6). Furthermore, antagonizing ERα with drugs,
such as tamoxifen is a successful treatment strategy in patients with ERα+ breast cancer
(6). GPER also increases epithelial cell proliferation in an E2-dependent manner;
however, unlike ERα, which classically behaves as a transcription factor, GPER is
responsible for rapid non-genomic E2-dependent signaling (28, 118, 135). Because
GPER is an estrogen receptor that increases cell proliferation, it was reasonable to believe
it plays a role in hormone responsive female cancers, including breast cancer. In vitro
evidence in breast cancer cell lines demonstrates GPER enhances cell proliferation and
migration through transactivation of the EGFR (118). Additionally, evaluation of clinical
samples detected GPER expression in 62% of invasive breast cancers, which correlated
with increased tumor size and presence of distant metastasis, and GPER was associated
with increased recurrence after tamoxifen treatment (119, 121). While these in vitro and
clinical data strongly implicated GPER in breast cancer progression, direct in vivo
evidence was still lacking. Accordingly, we investigated the in vivo impact of GPER
expression on breast cancer development, growth, and progression using the MMTVPyMT murine model of mouse carcinogenesis.
GPER KO mice were crossed with PyMT mice to generate PyMT GPER WT,
HET, and KO mice (WT/PyMT, HET/PyMT, KO/PyMT). Using this model, it was
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determined GPER does not affect early tumor development evidenced by no difference in
proliferation rate or extent of hyperplasia at 7 weeks of age. However, by 12 weeks of
age, tumors in KO/PyMT mice were smaller than tumors in WT/PyMT mice. Evaluation
of P-histone-H3 expression demonstrated the proliferation rate in tumors from KO/PyMT
was reduced compared with tumors from WT/PyMT mice, suggesting the difference in
tumor size is due to the effect of GPER on proliferation. Furthermore, KO/PyMT mice
contained fewer metastases compared to WT/PyMT mice, implicating GPER in breast
cancer metastasis and consistent with in vitro reports of GPER stimulating epithelial cell
migration (118). Collectively, these results establish a role for GPER in mammary tumor
growth and progression and are the first direct in vivo evidence for a role of GPER in
breast cancer. While these results are exciting, it is important to acknowledge the
KO/PyMT mouse is a global knockout, making it difficult to differentiate the mechanism
by which GPER regulates tumor growth. Therefore, an orthotopic transplant model was
used to differentiate the contribution of GPER expression in the tumor cell versus the
microenvironment.
WT/PyMT cells were orthotopically transplanted into WT and KO FVB mice to
assess the microenvironmental role of GPER on tumor size and distant metastasis. Tumor
size did not differ between WT and KO mice, suggesting the proliferative and survival
effects of GPER in the tumor parenchyma are dominant over any effect GPER may be
having in the microenvironment. However, there is no direct evidence in this model
demonstrating GPER expression in tumor cells increases proliferation or survival. To
determine the possible growth promoting effects of GPER in tumor epithelium, primary
WT/PyMT and KO/PyMT cells will be cultured and assessed for differences in
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proliferation rate as well as cell survival. While this simple experiment analyzes a direct
effect of GPER on epithelial cell proliferation, it does not account for epithelial-derived
secreted factors that may modulate the microenvironment. For example, GPER
stimulation causes the cleavage of HB-EGF, which could ultimately result in VEGF
production and increased angiogenesis, thus indirectly regulating tumor size (154). To
delineate these indirect tumor-promoting effects, an in-depth analysis of tumors derived
from WT/PyMT and KO/PyMT cells needs to be performed to assess differences in
vasculature and stromal cells.
Metastasis to the lungs of WT and KO mice bearing WT/PyMT tumors was also
assessed. While metastasis occurred in WT mice, no metastases were present in the lungs
of KO mice. These data suggest GPER in the microenvironment augments the ability of
tumors to metastasize, although the mechanism has not been elucidated. Multiple
modifications in the tumor microenvironment are responsible for increased metastasis,
including alterations to the ECM, increased blood vessel permeability, and signaling from
multiple cell types (139). Investigation into the mechanism of metastasis should initially
focus on gross differences between primary tumors in WT and KO mice. These
differences include modifications in the type of stromal collagen, changes in density or
distribution of vasculature, and the relative quantity of microenvironmental cell types,
such as fibroblasts and immune cells (139). Next, cultured tumor chunks will be
analyzed for secreted factors including growth factors and cytokines to determine if
GPER affects the production of factors regulating metastasis. Finally, the effects of
GPER in individual stromal cell types will be assessed. For example, an EGF-CSF-1
signaling axis occurs between macrophages and mammary tumor cells, which enhances
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metastasis (145). Thus, if GPER mediates the secretion of EGF from macrophages, it
may enhance metastasis through this signaling axis. Once individual cell effects are
determined, co-culture invasion assays with these individual cell types will be used in
combination

with

signaling

inhibitors

to

determine

the

mechanism

of

microenvironmental GPER-mediated metastasis. Furthermore, the ability for tumors to
survive and grow in the distant site can be affected by the microenvironment of the
metastatic organ (106). Therefore, an experimental metastasis model will be used in
which WT/PyMT cells are intravenously injected into WT and KO mice. This method
bypasses the invasion and intravasation steps required for metastasis and focuses on the
ability of the tumor cells to seed and survive at a distant site (155).
The reciprocal experiment was also performed in which KO/PyMT cells were
orthotopically transplanted into WT and KO mice. Tumors transplanted into KO mice
were significantly larger than those in WT mice, suggesting GPER in the
microenvironment hinders tumor growth. In a similar manner as described above, it will
be necessary to determine differences in vascular density and distribution and the relative
quantity of stromal cells to begin to understand how lacking GPER in the
microenvironment augments tumor growth. Further, investigation into the role of GPER
in individual stromal cell types will aid in understanding microenvironmental regulation
of KO/PyMT tumor size.
In contrast to tumor size, no difference was observed in the ability of KO/PyMT
tumors to metastasize in WT or KO mice. These data appear contradictory to the data
obtained from WT/PyMT tumors, which metastasize more frequently in WT mice than
KO mice. However, it is important to recognize that KO/PyMT tumors are larger in KO
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compared to WT mice, and tumor size is an independent risk factor for metastasis (146).
Therefore, to better assess the effects of microenvironmental GPER on metastasis of
GPER- tumors, KO/PyMT cells will be orthotopically transplanted into WT and KO mice
and the lungs will be assessed for metastasis when tumors are the same size as
determined by caliper measurements. The results from this experiment will clarify if
GPER in the microenvironment affects the ability of KO/PyMT tumors to metastasize or
if the metastasis-promoting effects of GPER in the microenvironment of KO/PyMT
tumors are being masked by the difference in tumor size.
Macrophages in the microenvironment have been implicated in tumor growth and
progression (89). Because GPER modulates the polarization of macrophages and
decreases the release of pro-inflammatory cytokines, bone marrow derived macrophages
(BMM) from WT and KO mice (WT/BMM and KO/BMM, respectively) were cotransplanted with WT/PyMT cells into a WT mouse (90). This experiment demonstrated
GPER expression in macrophages enhances tumor growth, but has no affect on the ability
of the tumor to metastasize. However, a confounding factor in this experiment was the
endogenous expression of GPER+ macrophages in the recipient mouse. Therefore, once
the tumor begins to form, endogenous GPER+ macrophages will be recruited to the tumor
site, potentially diluting the effects of KO/BMM. Furthermore, because the transplanted
macrophages were unlabeled, it is unclear how many were retained by the tumor.
Therefore, in the future this experiment will be conducted in transgenic mice allowing
conditional macrophage ablation such as MAFIA mice to deplete endogenous
macrophages (148). Tumors will be orthotopically transplanted into macrophagedepleted mice receiving adoptively transferred WT/BMM or KO/BMM. Differences in
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tumor size and metastasis with respect to GPER expression in macrophages will then be
assessed. Additionally, GPER-dependent macrophage polarization will be assessed in
vitro by analyzing secreted cytokines in WT/BMM and KO/BMM. Furthermore, coculture experiments with PyMT cells and WT/BMM and KO/BMM will be performed to
examine differences in tumor cell proliferation, survival, and invasion.
Ultimately, defining the role of GPER in breast carcinogenesis will determine if it
is a good candidate for targeted therapy. Inhibiting E2-dependent signaling is a successful
treatment paradigm in patients with ERα+ tumors (99, 103, 116). One of the most
common adjuvant therapies for breast cancer is tamoxifen, which antagonizes ERαdependent signaling in breast cancer. Although 70% of tumors express ERα and are
treated with tamoxifen, many become resistant to treatment (59). Furthermore, the 30%
of tumors that do not express ERα are ineligible for treatment with tamoxifen, often
leading to treatment with toxic chemotherapeutics (136). The discovery of GPER
revealed a novel, targetable E2-dependent signaling pathway that could help explain
tamoxifen resistance, as tamoxifen is a GPER agonist (120). Therefore, PyMT mice were
ovariectomized to remove the majority of circulating E2 and treated with E2, the GPERselective agonist G-1, and the GPER-selective antagonist G36 in the presence or absence
of E2. As expected, E2 increased tumor size and the extent of metastasis. G36 had no
effect on E2-dependent tumor size, suggesting the proliferative effect of ERα is dominant
to that of GPER, making GPER inhibition inconsequential in tumor size. However, G36
inhibited E2-mediated metastasis, demonstrating a role for GPER in mammary tumor
metastasis. Although G-1 enhances the proliferation of cultured breast cancer cells in
vitro, it did not affect the size of in vivo tumors. It is possible the effect of G-1 on the
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microenvironment inhibits tumor growth, negating its proliferative effect in the
epithelium. Additionally, G-1 did not affect the extent of metastasis, although G36
inhibited E2-mediated metastasis. These apparently contradictory results indicate ERα
and GPER may cooperate to enhance breast cancer metastasis. In vitro examination of
ERα- and GPER-dependent migration and invasion will help to clarify the role of each
receptor in metastasis and how they may interact to enhance metastasis. Further,
analyzing the effects of G36 on the tumor microenvironment will aid in understanding
how GPER may indirectly cooperate with E2 to increase the incidence of metastasis.
Finally, ERα expression in patient samples has been negatively correlated with lymph
node involvement and distant metastasis; however, ERα-positive samples will be
analyzed with respect to GPER to determine if GPER enhances metastasis in ERα+
tumors (64). The reciprocal analysis will also be done in GPER+ samples to reveal a
possible cooperation between GPER and ERα in metastasis. These data demonstrate
pharmacologically inhibiting GPER in vivo inhibits breast cancer metastasis. Therefore,
G36 may be a viable treatment to decrease tamoxifen resistance or to treat patients with
ERα- tumors.
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5.2 Overall Conclusions
This seminal work establishes an in vivo role for GPER in breast cancer growth
and metastasis. Prior to the discovery of GPER, the understanding of E2-dependent
effects in breast cancer was incomplete. Since that time, many studies have indicated a
possible role for GPER in breast cancer; however, this is the first in vivo demonstration
that GPER expression in both the tumor parenchyma and microenvironment enhances
tumorigenesis. Furthermore, pharmacologic inhibition of GPER was demonstrated to
decrease distant metastasis, the foremost cause of breast cancer-related mortality,
suggesting GPER is a good candidate for targeted therapy.
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